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Abstract
This work endeavours to explain molecular dynamic causes of resistance
in Human Immunodeficiency Virus (HIV) Integrase through simulation
of Prototype Foamy Virus (PFV) Intergrase interaction with DNA in the
presence of Raltegravir (RLT) for the purpose of efficient and automatic
drug ranking of Integrase inhibitors.
Chapter One introduces the problem of Acquired Immunodeficiency
Syndrome (AIDS) through both historical perspective and current situ-
ation by some crude analysis of geographical and social distribution.
Similarly HIV is introduced both as a biological species and biochem-
ical system with particular focus on Integrase, one of its essential protein
enzymes.
Chapter Two contains methods of Molecular Dynamics which
are used extensively throughout this thesis (Chapters Four to Six), as
well as some scientific background to those methods.
Chapter Three describes efforts towards generating viable struc-
ture of HIV Integrase intasome for the purpose of Molecular Dynamic
analyses. Methods of homology modelling are employed using known
homologues of HIV Integrase as input data.
The remaining parts of this thesis are made up of three experimental
chapters describing Molecular Dynamic simulations of several biochem-
ical systems and their analyses.
Contents
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.1. Historical outline . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2. Distribution and mortality . . . . . . . . . . . . . . . . . . . . 11
1.3. HIV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.1. Classification . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3.2. Structure . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.3. Lifecycle . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.4. Integrase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.4.1. Integration process . . . . . . . . . . . . . . . . . . . . 18
1.4.2. Domain organization . . . . . . . . . . . . . . . . . . . 19
1.4.3. Common motifs . . . . . . . . . . . . . . . . . . . . . . 20
1.5. Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.5.1. Drug Design . . . . . . . . . . . . . . . . . . . . . . . . 21
1.5.2. Resistance . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.6. Goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2. Methods of Molecular Dynamics . . . . . . . . . . . . . . . . . 26
2.1. Quantum mechanics . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2. Newtonian approach . . . . . . . . . . . . . . . . . . . . . . . . 27
2.2.1. Equations of motion . . . . . . . . . . . . . . . . . . . . 28
2.2.2. Calculating forces . . . . . . . . . . . . . . . . . . . . . 29
2.2.3. Integration algorithm . . . . . . . . . . . . . . . . . . . 30
2.3. Coarse grained simulation . . . . . . . . . . . . . . . . . . . . . 31
Contents
2.4. Potential parametrisation . . . . . . . . . . . . . . . . . . . . . 32
2.5. Statistical methods . . . . . . . . . . . . . . . . . . . . . . . . 34
2.5.1. Trajectory interpretation . . . . . . . . . . . . . . . . . 34
2.5.2. Correlation coefficient . . . . . . . . . . . . . . . . . . . 35
2.6. Binding Energy . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.6.1. Continuum solvation methods . . . . . . . . . . . . . . 36
2.7. Thermodynamic view of binding affinity . . . . . . . . . . . . . 38
3. Homology Modelling of HIV integrase . . . . . . . . . . . . . . 41
3.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.1.1. Proteins structure . . . . . . . . . . . . . . . . . . . . . 41
3.1.2. Structure determination . . . . . . . . . . . . . . . . . 44
3.1.3. Phylogenetics . . . . . . . . . . . . . . . . . . . . . . . 44
3.2. Methods and tools . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.2.1. Sequence alignment and Clustering . . . . . . . . . . . 47
3.2.2. Modelling . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3. Input data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3.1. HIV-1 Integrase Homologues . . . . . . . . . . . . . . . 49
3.3.2. HIV-1 Integrase partial structures . . . . . . . . . . . . 53
3.3.3. Theoretical models . . . . . . . . . . . . . . . . . . . . 56
3.4. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.4.1. Sequence alignment . . . . . . . . . . . . . . . . . . . . 57
3.4.2. Phylogenetics . . . . . . . . . . . . . . . . . . . . . . . 57
3.4.3. Modeller . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.4.4. Initial model . . . . . . . . . . . . . . . . . . . . . . . . 58
3.4.5. Monomeric apoprotein molecule . . . . . . . . . . . . . 59
3.4.6. Modelling the dimer . . . . . . . . . . . . . . . . . . . . 59
3.4.7. Challenges . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.4.8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 61
4. PFV Integrase intasome binding energy in MD . . . . . . . . 62
4.1. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.1.1. Input data and Simulation parameters . . . . . . . . . 63
2
Contents
4.1.2. Model validation . . . . . . . . . . . . . . . . . . . . . . 66
4.1.3. Simulation . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.1.4. Binding Energy analyses . . . . . . . . . . . . . . . . . 69
4.1.5. Principal Components Analysis . . . . . . . . . . . . . 69
4.2. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.2.1. Minimisation and Equilibration . . . . . . . . . . . . . 70
4.2.2. System stability per residue . . . . . . . . . . . . . . . 70
4.2.3. Binding Free Energy . . . . . . . . . . . . . . . . . . . 73
4.2.4. Distribution of results per replica . . . . . . . . . . . . 74
4.2.5. Per residue decomposition . . . . . . . . . . . . . . . . 75
4.2.6. Principal Components Analysis . . . . . . . . . . . . . 78
4.2.7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 79
5. Optimal system size for accurate simulation of PFV
Integrase active centre . . . . . . . . . . . . . . . . . . . . . . . . 81
5.1. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.1.1. Input data and Simulation parameters . . . . . . . . . 82
5.1.2. Binding Energy . . . . . . . . . . . . . . . . . . . . . . 84
5.1.3. Symmetry . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.2. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.2.1. Equilibration . . . . . . . . . . . . . . . . . . . . . . . . 85
5.2.2. System stability per residue . . . . . . . . . . . . . . . 87
5.2.3. Binding Free Energy . . . . . . . . . . . . . . . . . . . 88
5.2.4. Distribution of results per replica . . . . . . . . . . . . 89
5.2.5. Binding energy decomposition . . . . . . . . . . . . . . 89
5.2.6. Symmetry . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2.7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 93
6. Effects of HIV N155H mutant analogue PFV N224H on
measured binding energy . . . . . . . . . . . . . . . . . . . . . . 94
6.1. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
6.1.1. Input data and Simulation parameters . . . . . . . . . 95
6.1.2. Binding Energy . . . . . . . . . . . . . . . . . . . . . . 96
3
6.1.3. Symmetry . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.2. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.2.1. Binding Free Energy . . . . . . . . . . . . . . . . . . . 97
6.2.2. Symmetry . . . . . . . . . . . . . . . . . . . . . . . . . 97
6.2.3. Distribution of results per replica . . . . . . . . . . . . 98
6.2.4. Binding energy decomposition . . . . . . . . . . . . . . 100
6.2.5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 103
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
List of Tables
1.1 HIV prevalence statistics, regions . . . . . . . . . . . . . . . . . . . 11
1.2 HIV prevalence statistics, women and children . . . . . . . . . . . 12
3.1 PDB structures breakdown . . . . . . . . . . . . . . . . . . . . . . 44
3.2 Multiple sequence alignment of lentiviral integrases . . . . . . . . 57
4.1 Binding energy components . . . . . . . . . . . . . . . . . . . . . . 73
4.2 Residues notable for their binding energy contributions . . . . . . 78
4.3 Binding energy contributions of non-protein residues . . . . . . . . 78
4.4 Correllation between nc trajectories PCs and MM-PBSA . . . . . 80
5.1 Wildtype subsystems used in simulations . . . . . . . . . . . . . . 84
5.2 RMSD distribution for all sizes of simulation system . . . . . . . . 85
5.3 Binding energy components for the dimer . . . . . . . . . . . . . . 89
5.4 Energy decomposition per unit within a dimer . . . . . . . . . . . 90
5.5 Energy decomposition per residue within a unit . . . . . . . . . . 92
6.1 Mutant subsystems used in simulations . . . . . . . . . . . . . . . 95
6.2 Comparison of RLT binding energy with N224H vs wildtype . . . 97
6.3 Comparison of RLT binding energy between dimers and
outstanding dh11:B . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.4 Energy decomposition per residue within a unit . . . . . . . . . . 102
List of Figures
1.1 Lentivirus structure . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.2 Lentivirus genome . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.3 Integrase domain organization . . . . . . . . . . . . . . . . . . . . 19
1.4 HIV-1 integrase CCD residues associated with resistance to INSTI 23
1.5 HIV-1 integrase mutants resistance to INSTI . . . . . . . . . . . . 24
2.1 Interactions within molecule . . . . . . . . . . . . . . . . . . . . . 29
3.1 Peptide bond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Protein tertiary structure . . . . . . . . . . . . . . . . . . . . . . . 43
3.3 ASV Integrase, PDB:1CXQ . . . . . . . . . . . . . . . . . . . . . . 49
3.4 RSV Integrase, PDB:1C0M . . . . . . . . . . . . . . . . . . . . . . 50
3.5 SIV Integrase, PDB:1C6V . . . . . . . . . . . . . . . . . . . . . . . 50
3.6 MVV Integrase, PDB:3HPG . . . . . . . . . . . . . . . . . . . . . 51
3.7 HIV-2 Integrase, PDB:3F9K . . . . . . . . . . . . . . . . . . . . . 51
3.8 PFV Integrase, PDB:3L2Q . . . . . . . . . . . . . . . . . . . . . . 52
3.9 HIV Integrase core domain, PDB:1QS4 . . . . . . . . . . . . . . . 53
3.10 HIV Integrase CCD and CTD, PDB:1EX4 . . . . . . . . . . . . . 54
3.11 HIV Integrase NTD and CCD, PDB:1K6Y . . . . . . . . . . . . . 55
3.12 Phylogenetic tree of lentiviral integrases . . . . . . . . . . . . . . . 58
3.13 IN monomer model . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.14 Symmetric IN dimer model . . . . . . . . . . . . . . . . . . . . . . 60
3.15 Asymmetric IN dimer model . . . . . . . . . . . . . . . . . . . . . 60
4.1 Complete structure of PFV intasome . . . . . . . . . . . . . . . . 63
4.2 Active centre of PFV intasome . . . . . . . . . . . . . . . . . . . . 64
4.3 Structure of RLT . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.4 Restricted part of DNA in PFV structure . . . . . . . . . . . . . . 68
4.5 Evolution of RMSD for unrestricted PFV monomer . . . . . . . . 71
Chapter 0. List of Figures
4.6 Evolution of RMSD for partially restricted PFV monomer . . . . 71
4.7 RMSF per residue . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.8 Normalised Frequency distribution function . . . . . . . . . . . . . 74
4.9 Binding Free Energy results from MM-PBSA analyses . . . . . . . 75
4.10 Binding free energy per residue . . . . . . . . . . . . . . . . . . . . 76
4.11 Residues contributing to calculated binding energy . . . . . . . . . 77
4.12 Principal Components Eigenvalues . . . . . . . . . . . . . . . . . . 79
5.1 Complete structure of PFV intasome dimer . . . . . . . . . . . . . 83
5.2 Comparison of RMSD distribution . . . . . . . . . . . . . . . . . . 86
5.3 RMSF per residue for various system sizes . . . . . . . . . . . . . 87
5.4 Binding Free Energy results from MM-PBSA analyses . . . . . . . 90
5.5 Binding free energy per residue . . . . . . . . . . . . . . . . . . . . 91
5.6 Binding Free Energy correlation between dimer units . . . . . . . 92
6.1 Binding Free Energy correlation between mutant units . . . . . . . 98
6.2 Binding Free Energy results from MM-PBSA analyses . . . . . . . 99
6.3 Binding Free Energy throughout the simulation of dh11:B . . . . . 99
6.4 Binding free energy per residue . . . . . . . . . . . . . . . . . . . . 101
6.5 Mutant active site residues . . . . . . . . . . . . . . . . . . . . . . 105
6.6 Mutant active site close-up . . . . . . . . . . . . . . . . . . . . . . 106
7
Acronyms
AIDS Acquired Immunodeficiency Syndrome. 1, 10–12
ASV Avian Sarcoma Virus. 49
CCD Core catalytic domain. 19, 49, 51
CHMP EU Committee for Medicinal Products for Human Use. 21
CTD C-terminal domain. 20, 49
ELV Elvitegravir. 19, 23, 24, 52
FDA United States Food and Drug Administration. 21
GAFF General Amber Forcefield. 64
HIV Human Immunodeficiency Virus. 1, 10–12, 14–18, 20–22, 24, 41,
45, 48, 49
IBD Integrase Binding Domain. 51
IN Integrase. 14, 15, 21, 41, 48, 62
INSTI Integrase strand transfer inhibitor. 19, 62
LEDGF Lens epithelium-derived growth factor. 51
LTR long terminal repeat. 17, 19, 45
MD Molecular Dynamics. 26, 41, 62
MM Molecular Mechanics. 27
MM-GBSA molecular mechanics generalised Born surface accessibility.
36, 38, 62, 69
MM-PBSA molecular mechanics Poisson–Boltzmann surface accessib-
ility. 36–38, 62, 69
MVV Maedi-Visna Virus. 51
Acronyms
NED N-terminal extension domain. 20
NMR Nuclear Magnetic Resonance. 26, 48
NTD N-terminal domain. 19, 20, 51
PCA principal components analysis. 69
PDB Protein Data Bank. 47
PFV Prototype Foamy Virus. 1, 52, 62
PIC pre-integration complex. 19
PR Protease. 15
QM Quantum Mechanics. 26
RESP Restrained Electrostatic Potential. 64
RLT Raltegravir. 1, 19, 21–24, 38, 52, 62, 63, 69
RMSD root mean square deviation. 34, 66, 67, 85
RMSF root mean square fluctuation. 34, 70
RSV Rous Sarcoma Virus. 18, 49
RT Reverse transcriptase. 15
SIV Simian Immunodeficiency Virus. 13, 47, 50
9
1. Introduction
1.1. Historical outline
The oldest —retrospectively identified— case of AIDS infected pa-
tients in Europe are a three-member Norwegian family, who all died
from AIDS in 1970s. Although their routes of infection were not proven,
the family history suggests the man contracted HIV during his visit in
Africa as a sailor before 1966 and subsequently infected his wife, who as
a result gave birth to an infected daughter[2]. Several other cases were
identified in tissue samples collected from various African patients during
60s–70s[3].
AIDS was diagnosed and defined for first time in USA in 1981. The
syndrome was initially known as Gay-related immune deficiency
(GRID), or more colloquially as the gay plague, as it was mostly dia-
gnosed within the gay communities of California and New York. It
had been found that the main routes of contagion were homosexual
intercourse[4], intravenous drug administration[5] and blood transfusion.
The name was changed to AIDS upon growing number of diagnoses with
heterosexual men and women. HIV was isolated from AIDS patients in
1983[6][7].
In 2008 alone approximately 2 million people died from AIDS re-
lated causes and an estimated 38.6 million were living with HIV around
the world[8], the overwhelming majority of whom live in Sub-Saharan
Africa[9]. The number of new infections peaked around 1997 and has
kept falling ever since, thanks to education, prevention and introduc-
tion of antiretroviral therapies. Similarly, the number of AIDS-related
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deaths is falling since 2004, thanks to both the decreasing number of new
infections and more efficient therapies. In developed countries AIDS is
beginning to be rather treated as a chronic than deadly disease. The
total number of HIV infected individuals has probably peaked around
2009 within the measure of uncertainty[9].
1.2. Distribution and mortality
The total HIV adult prevalence ratio in the world is estimated at 0.8%
but the distribution is not uniform. Above average ratios are found in
Sub-Saharan Africa (5%) and the Caribbean (1%) and the lowest in East
Asia (0.1%). Sub-Saharan Africa is the largest pool of HIV infections
with more than 22 million people living with HIV, or 68% of the global
number of infected. It is also by far the most affected region in terms of
AIDS-related deaths — 72% of global number of AIDS-related deaths in
2009 occurred in that region. For more detailed data see Table 1.1.
Region Carriers Infections Prevalence Deaths
Sub-Saharan Africa 22.5 mln 1.8 mln 5.0 1.3 mln
Middle East and
North Africa
460 000 75 000 0.2 24 000
South and South
East Asia
4.1 mln 270 000 0.3 260 000
East Asia 770 000 82 000 0.1 36 000
Oceania 57 000 4 500 0.3 1 400
Latin America 1.4 mln 92 000 0.5 58 000
Carribean 240 000 17 000 1.0 12 000
Eastern Europe
and Central Asia
1.4 mln 130 000 0.8 76 000
Western and Cent-
ral Europe
820 000 31 000 0.2 8 500
North America 1.5 mln 70 000 0.5 26 000
Total 33.3 mln 2.6 mln 0.8 1.8 mln
Table 1.1. Regional HIV and AIDS statistics for 2009; Total number of
HIV carriers, new infections, adult prevalence ratio and AIDS-related
deaths[9]
The main identified risk groups are male homosexuals, female sex-workers
and intravenous drug users. The detailed breakdown between risk groups
11
Chapter 1. Introduction
vary strongly among regions and countries. In Sub-Saharan Africa, where
68% of carriers live, the majority of people living with HIV are women.
The numbers are similar for Caribbean, Eastern Europe and Central
Asia, Middle East and North Africa, and Oceania, where 40–50% of
carriers are women. The same regions also have higher than average
prevalence of HIV among children, mostly as a result of mother-to-child
transmissions, with the exception of Eastern Europe and Central Asia.
Conversely, in highly developed countries of North America, Western
and Central Europe, and East Asia, the disease remains more prevalent
within men having sex with men, with women constituting less than 30%
of infected. Similarly, prevalence of HIV among children in Western and
Central Europe, and North America remains below 0.5% (Table 1.2).
Region Total Women % Children %
Sub-Saharan Africa 22.5 mln 12.1 mln 54 2.3 mln 10
Middle East and
North Africa
460 000 210 000 46 21 000 4.6
South and South
East Asia
4.1 mln 1.4 mln 34 150 000 3.7
East Asia 770 000 220 000 29 8 000 1.0
Oceania 57 000 25 000 44 3 100 5.4
Latin America 1.4 mln 490 000 35 36 000 2.6
Carribean 240 000 120 000 50 17 000 7.1
Eastern Europe
and Central Asia
1.4 mln 690 000 49 18 000 1.3
Western and Cent-
ral Europe
820 000 240 000 29 1 400 0.2
North America 1.5 mln 270 000 18 4 500 0.3
Total 33.3 mln 15.8 mln 47 2.6 mln 7.7
Table 1.2. Regional HIV and AIDS statistics for 2009; Women and Chil-
dren living with HIV as a percentage of infected population[9]
1.3. HIV
HIV was isolated in 1983 from a single AIDS patient and proposed
as the infectious agent[6]. It is classified as a member of lentiviruses
family, due to very long incubation period. It is generally accepted that
12
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HIV evolved from Simian Immunodeficiency Virus (SIV) naturally found
in African primates. Phylogenetic studies indicate there are two subspe-
cies — HIV-1, more aggressive and more closely related to SIV strains
found in the great ape Chimpanzee; and HIV-2, mostly limited to West
Africa and closely related to the Sooty mangabeys strain of SIV. The
data suggests the HIV species is polyphyletic, meaning two subspecies
are more closely related to respective SIV strains than to each other and
form only two small subbranches of the SIV clade[10]. The implication
of this finding is that the virus adapted to humans at least twice. More
detailed analysis reveals at least two transmissions took place for each of
the subspecies[11].
SIV itself is been estimated to prey on various primate species for
thousands of years but the transmissions to humans are most likely to
have occurred in first half of the twentieth or late ninetieth century. The
results of phylogenetic analyses put the estimated date of transmission
around the 1950s, which would be consistent with the earliest identified
infections.
1.3.1. Classification
Virus classification —despite using similar naming convention as for
cellular organisms taxonomy— does not follow the same rules, partially
due to the debated status of viruses themselves as living organisms.
There are therefore many unrelated classification systems depending on
features taken into account. Most existing classifications include both
virus properties (like type of nucleic acid, morphology, modes of replica-
tion) and the host classification.
Retroviruses are a family (Retroviridae) of viruses. Their charac-
teristic feature is the process of reverse transcription, which —when
discovered[12][13]— caused modification of the Central Dogma of Molecu-
lar Biology [14], only thirteen years after it was proposed by Francis Crick
at a symposium held at University College London in 1957[15]. After
13
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entering the host cell, one of the virus enzymes Reverse transcriptase,
translates viral RNA into DNA[12][13] which is then integrated into the
host genome[16] by Integrase (IN). The integrated virus or provirus is
ready to be replicated by the host whenever the infected part of genome
is activated for transcription and expression. The third of essential retro-
virus enzymes is Protease reponsible for cleaving expressed polypeptides
into functional proteins.
Lentivirus —from Latin lentus for slow, inactive— is a genus of Ret-
roviridae characterised by slow incubation. Their specific trait of having
two —usually identical— single strands of RNA instead of one as most
viruses do makes them in some aspects behave like diploid eukaryotes.
When two different parent genomes are present they may recombine in
a manner similar to that of higher organisms. Lentiviruses also have the
unique ability to infect non-cycling cells, unlike other retroviruses which
—even after entering the cell— can only integrate its genome if the nuc-
lear membrane is broken (e.g. during natural cell division)[17]. Both
these traits together make Lentiviruses very useful tools as vectors[18]
e.g. for gene therapy[19][20]. The same traits, unfortunately, make HIV
the causative agent for one of the most notorious pandemics of late 20th
century.
HIV phylogenetic relations within the whole family is presented in
closer details in chapter 3.
1.3.2. Structure
A virion of a typical retrovirus is an entity about 100 nm of diameter.
Like many viruses it consists of a glycoprotein envelope, the genome and
several enzymatic proteins as seen in Figure 1.1.
The outermost layer of a virion, the so called envelope, consists of
a lipid membrane with glycoproteins transmembrane TM (gp411) and
surface envelope SU (gp120). TM–SU complex shows similarities to other
1 all protein masses in kDa are based on HIV example
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Figure 1.1. HIV-1 virion structure as a typical example of Lentivirus,
adapted from[21].
viral membrane fusion proteins[22], with TM being a homotrimer build
of three transmembrane α-helices and a functional external N-terminal
fusion domain[23], and trimeric antigenic structure of SU[24]. The weak
interaction within the complex is responsible for its short half-life of 30
hours and consequently rapid decay of virus infectivity[25].
In the virion one can find all three enzymes essential for its repro-
duction and maturation. Approximately 80 copies of those enzymes
are found per virion[25]. Reverse transcriptase (RT), and IN are found
packed closely with the RNA in the conical capsid. Protease (PR) is
still active during maturation phase —after leaving the host— before
the virion acquires its final shape.
The structure of a virion is shaped by three distinct proteins. Matrix
protein MA (p17) forms icosahedral inner layer of the membrane[26]. A
conical Capsid built of CA (p24) separates viral nucleus from lateral
body of unknown composition[27]. Finally Nucleocapsid protein NC
(p7) is packed closely with RNA and both enzymes essential for repro-
duction (RT, IN)[28][29].
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Lentivirus genomes consist of two RNA strands, each coding the
same three polypeptides gag, pol, env which are later processed into
functional proteins, at different stages of the virus life cycle. There are
also several smaller genes encoding helper proteins. The schematics of
lentiviral genome at example of HIV is shown in Figure 1.2.
Figure 1.2. HIV-1 genome as a typical example of Lentivirus, adapted
from[21].
The gag gene (Group-specific Antigen) encodes a precursor of struc-
tural capsid proteins, NC, CA, MA.
The pol gene (Polyprotein) encodes a precursor of viral enzymes,
Reverse transcriptase, Integrase and Protease.
The env gene (Envelope) encodes a precursor of envelope proteins,
TM and SU.
1.3.3. Lifecycle
HIV virion recognises and binds the CD4 receptor of the T4 lymphocyte[30].
The surface envelope protein responsible for interaction SU (gp120) is one
of two proteins encoded by env gene. The high affinity between gp120
and CD4 causes downmodulation of CD4 receptors during later stage
of infection and subsequently “superinfection interference”[31], although
other factors have been suggested[32]. CD4 is not the only receptor
identified as involved in virus entry[33]. The complex of gp120/CD4
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and coreceptors is finally activated by TM (gp41, the other part of env)
leading to membrane fusion[34][33]. It has been also shown that — at
least HIV-2 — can enter cells stripped of CD4[35].
The action characteristic for retroviruses is performed by HIV RT, a
heterodimer in which both parts (p66 and p51) are encoded by the same
segment of pol. The shorter p51 is the result of cleaving out 15kDa C-term
segment of p66 by PR. Because HIV, like all lentiviruses, has two strands
of RNA, the RT, with its relatively low affinity to its template, is able to
switch during the process of transcription[36]. This template switching
combined with high mutation rate (3 · 10−5 per cycle[37]) together with
their recombination, leads to high heterogeneity and subsequently to a
rapid evasion of the host’s natural immune response as well as of designed
therapies[38].
The DNA is transported into cell nucleus as part of the pre-integration
complex (PIC) but the mechanism of transfer, unique for Lentiviruses is
not yet properly explained in detail[38]. After entering the nucleus HIV
IN (p32) performs the process common among Retroviruses, of fusing
viral DNA with that of the host. The integrated viral genome or provirus
is then treated by the host as any other part of its own genome. The
closer look at IN and the process will be presented in section 3.3.
Integrated viral DNA in the form of provirus is unrecognisable as
alien for the host cell. It is indiscriminately expressed by the host. The
viral long terminal repeat (LTR) (see Figure 1.1) act as an initiation
sequence for transcription enzymes. The activity is significantly increased
in the presence of Transcriptional transactivator (tat) protein[39][40].
Transcibed RNA is spliced in the process aided by the “regulator of
expression of viral proteins” (rev protein)[41]. Transcription is followed
by translation to viral protein precursors.
The assembly of new virion takes place at the host’s membrane. Gag
proteins are necessary for the successful assembly of virion-like particles
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in vitro[21]. CA–NC complex in vitro selfassembly efficiency is signi-
ficantly increased by the presence of RNA[42]. The env glycoprotein
synthesised on ER[43][44] is subsequently oligomerised during its trans-
port through the Golgi[45] and cleaved into TM and SU proteins[46][47].
Other interactions between viral proteins – essential for proper assembly
– have been identified, too numerous to be presented in this work. Fi-
nally the assembled virion is released from the host in the process of
budding[48].
The GagPol polyprotein processing (cleavage) by PR is the last stage
of virus replication[49]. Unlike most other retroviruses, which mature
after leaving the host[50], HIV protease probably performs its role before
virion release from the host, during the final stage of assembly on the
host membrane[51]. The maturation phase is reflected by large morpho-
logical change of the virion and emergence of a conical capsid around its
genome[52].
1.4. Integrase
The importance of integration for lentiviruses was recognised since
the discovery of Rous Sarcoma Virus (RSV) provirus identified in the
DNA of infected cell homology to RSV genome[53] and confirmed by
later research. It had been shown early that selective mutation in IN en-
coding segment of pol gene stops virus integration[54] and consequently
its reproduction[55]. This fact makes Integrase potentially a good target
for inhibition therapy.
1.4.1. Integration process
After transcription of viral RNA into DNA by RT the Integrase takes
turn and the Integration begins. The process consists of three phases,
first two of which are performed by Integrase[56].
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3’-end processing
The integrase removes several nucleotides from 3’-end LTR of the
viral DNA. This exposes the invariant CAOH-3’ dinucleotide that will
participate in the integration. The preprocessed form of DNA bound to
IN is called pre-integration complex (PIC).
Strand transfer
The stage begins with cleavage of cellular DNA by IN and completes
with joining processed 3’-ends of viral DNA with cleaved 5’-end cellu-
lar DNA. This is the stage targeted by both available Integrase strand
transfer inhibitors(INSTIs) — RLT and Elvitegravir (ELV)[57].
Repair
The final stage of integration is left to cellular enzymes. The host
repair enzymes connect viral 5’-end with the open 3’-end of cellular DNA.
1.4.2. Domain organization
Figure 1.3. Domain organization and secondary structural elements of
representative IN proteins, adapted from[57]. Domains color-coded and
labelled. Also labelled HHCC residues of Zinc finger motif within NTD
and DDE of catalytic triad in CCD.
The related retroviral integrases share common features of both se-
quence and structure[57]. The domain organization of selected members
of the family presented in Figure 1.3 show three analogous domains —
N-terminal domain (NTD) with Zinc finger motif, Core catalytic domain
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(CCD) with catalytic DD(35)E and C-terminal domain (CTD). PFV dif-
fers from most integrases in having N-terminal extension domain (NED).
In this work NED will be referred to as part of NTD for simplicity.
1.4.3. Common motifs
Zinc finger
Zinc finger motif (Znf) usually contains tetrahedral zinc cation in-
creasing structural stability of a domain. In the class of Znf found in IN
NTD the cation is chelated by two histidines (H) and two cysteines (C)
and is thus called HHCC, Zn–HHCC, or Cys2His2.
D,D(35)E
Integrase’s catalytic triad — D,D(35)E motif of two aspartates (D)
and one glutamate (E). The number 35 indicates a conserved number
of residues in between the second aspartate and glutamate, while the
distance between two aspartates varies among species. In some resolved
structures (described in chapter 3), one or two divalent cations have been
found chelated by triad’s residues (in which case also called Mg2–DDE).
1.5. Therapies
The first approved treatment for HIV infected patients was Nucle-
otide Reverse Transcriptase Inhibitor (NRTI) zidovudine approved in
1987[58]. The drugs inhibit virus replication during the process of reverse
transription, specific to retoviruses family. Shortly after, the first drug
resistant HIV strains were reported[59]. This fact, combined with the
high toxicity of early treatments led to a high concentration of efforts and
resources on finding ever better therapy. In subsequent years, new types
of therapies and new targets for drug therapies were acquired, Protease
Inhibitors (PI) in 1995, Non-Nucleoside Reverse Transcriptase Inhibitors
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(NNRTI) and Combination Therapies in 1997, Fusion Inhibitors in 2003
and finally Integrase Inhibitors in 2007.
The first Integrase inhibitor — RLT — was approved for use in USA
market by United States Food and Drug Administration (FDA) in Oc-
tober 2007[60] and for the European market by the EU Committee for
Medicinal Products for Human Use (CHMP) in December 2007. RLT
inhibits the strand transfer stage of HIV DNA integration (section 1.4)
by binding IN.
Regardless of drug category, the expected effect by slowing down
the virus replication is reducing the number of virus infected cells in
the patient’s body, slowing the advance of disease and reducing the
risk of further infections. When applied to pregnant and breastfeed-
ing women, therapies are expected to reduce the risk of mother-to-child
transmission[61].
1.5.1. Drug Design
The first use of medicine to cure or relief illnesses fades in the deep
prehistory, hence no written account of the discovery. For ages the pro-
cess of discovering cures was largely chaotic and done by untrained pro-
fessionals or by pure chance. Similarly medical practitioners had close to
no understanding of the nature of illnesses or drug workings.
Nowadays, drug design routinely uses atom level description of re-
ceptor structure as a target for a drug. The target usually being a mo-
lecule taking part in one of the critical pathways responsible for spreading
or the advance of a disease. In the case of HIV, therapies typically target
HIV enzymes, with the exception of Fusion Inhibitors or CCR5 receptor
antagonists targeting process of virus fusion with the host cell. One
of the first steps in efficient and accurate drug design relies heavily on
detailed receptor structure to predict the interactions between the drug
and the receptor. In case of lack of reliable structure, homologous protein
or partial structure may be used as a first approximation.
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1.5.2. Resistance
One of the biggest obstacles to eradication of viral diseases is the virus
acquiring resistance to administered drugs. Viruses naturally show vari-
ation in genome, and occasionally if these mutations increase their res-
istance to the medicine present in the patient’s system, the virus evolves
toward more resistant to that particular drug by a means of natural
selection[62]. HIV, being a Lentivirus, is a particularly evasive target
due to a combination of reasons, among them having a doubled genome
and long incubation period. Having a doubled genome gives lentiviruses
not only a double chance of having resistance mutations but also a power
of recombination in case of a patient infected with two strains of different
origin. The causes for spreading of drug resistant HIV strains may be
divided in two categories — patient noncompliance and nonsuppressive
antiviral therapy[63].
Even during 48 week clinical BENCHMRK studies of RLT, two resist-
ance pathways were observed in 105(23%) of 462 patients ([60], [64], [65]).
The aim of this work is thus to use molecular simulations in drug binding
characterisation, with the eventual goal of quantitatively describing the
impact of mutations upon it.
Two main RLT resistant mutations are N155H and Q148H/R/K with
10- and 25-fold in Vivo resistance, respectively. Other mutations re-
ported include L74M, E92Q, E138K, G140S/A, and G163R. For ELV,
two main mutations are T66I and E92Q (37- and 36-fold reduced sus-
ceptibility, respectively). Other mutations reported are H51Y, T66I,
Q95K, E138K, Q146P, S147G, and E157Q. Mutations selected from viral
samples obtained from drug-resistant patients for the comparative study
by Marinello et al. are shown in Figure 1.4 and their results showing
great variance in efficacy in Figure 1.5.[66]
Growing number of drug resistant mutations led to increasing import-
ance of combination therapies and is a motivating factor for development
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Figure 1.4. HIV-1 integrase CCD residues associated with resistance to
RLT or ELV. (A) Linear representation. (B) Three-dimensional structure
(PDB:1BI4). Catalytic acidic residues (DDE motif) are shown in red,
mutations in dark blue. Figure adapted from [66].
of patient specific therapies. Since any mutation usually give resistance to
a limited number of inhibitors —or to put it more accurately, a different
level of resistance to different inhibitors— it is desired to choose a drug
working most effectively towards the particular strain of virus. Virus
genome is now routinely being sequenced upon a patient’s diagnosis for
consideration in clinical decisions. Growing knowledge databases and
expert systems are aiding clinicians in decision making, but the rapid
evolution of virus makes it important to develop more sophisticated,
accurate and efficient methods. A number of projects exploring the
possibility of modelling inhibitor binding to target receptor by means
of molecular dynamics have been undertaken. It is postulated that
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Figure 1.5. Comparative impact of the HIV-1 integrase mutations on
integrase strand transfer inhibition by RLT and ELV. Figure adapted
from [66].
inhibitor’s adequacy toward a given mutant may be predicted by cal-
culating its binding free energy with the receptor. The molecular
dynamics methods, as well as methods for binding energy calculation are
explored in chapter 2.
1.6. Goals
All known Integrase Inhibitors were successfully designed without a
complete knowledge of the HIV Integrase structure. Several partial struc-
tures, as well as structures of homologous proteins are known. Having
complete Integrase complex structure could have a tremendous positive
efect on the drug design process, but the HIV Integrase heretofore eludes
all eforts of crystallisation. It is therefore suggested to use theoretical
models based on homologous proteins and partial HIV Integrase struc-
tures to research the behaviour of the drug target.
This thesis documents attempts to generate a viable homologous
model for HIV Integrase and to provide a good explanation of bind-
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ing active centre behaviour and structural factors behind drug resistant
mutations by an analysis of the structural and thermodynamic properties
of Prototype Foamy Virus engineered complex with DNA and Ralteg-
ravir, by using the methods of Molecular Dynamics and Free Binding
Energy calculations.
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2. Methods of Molecular Dynamics
The biochemical systems such as Integrase intasome are inherently
dynamic. However, the information obtained through methods of X-ray
crystallography and Nuclear Magnetic Resonance (NMR) is of a static
nature. Therefore Molecular Dynamics (MD) methods are commonly
employed in research to gain deeper insight in their dynamic structure
and function through simulation.
Various approaches have been designed to fit the purpose of research
of which only some will be explored here. MD methods can be used to
refine structures by minimising systems’ internal energy or to explain
dynamics of chemical reactions.[67]
2.1. Quantum mechanics
Although Quantum Mechanics (QM) tells us that the complete de-
scription of any system is fundamentally beyond our cognition and clas-
sical mechanics is only its inaccurate approximation, it is rarely used in
biochemistry due to very high computational cost. Evolution of quantum
system is defined in terms of the time dependent Schro¨dinger equation:
ih¯
∂Ψ
∂t
= HˆΨ (2.1)
where Ψ is the wave function describing probability amplitude, ih¯ ∂
∂t
is
the energy operator and Hˆ is the Hamiltonian operator describing the
system’s energy.
To properly describe system evolution, one needs to find the wave-
function by solving the equation. The equation can only be solved analyt-
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ically for the very simplest systems (e.g. a single particle in a potential,
hydrogen atom). For a single particle in a potential the equation takes
the form:
ih¯
∂
∂t
Ψ(x, t) = − h¯
2
2m
∇2Ψ(x, t) + Vˆ (x)Ψ(x, t) (2.2a)
Hˆ = Tˆ + Vˆ (2.2b)
Tˆ = − h¯
2
2m
∇2 (2.2c)
Vˆ = potential energy operator (2.2d)
where x is particle position and t is time.
For bigger systems complexity grows exponentially, quickly making it
unfeasible to solve the equation by analytical methods, and very expens-
ive to compute numerically. Heuristic numerical methods using various
approximations are therefore employed for medium-sized systems, includ-
ing small organic molecules like drugs. However, most of the systems bio-
chemistry regularly deals with are much more complex, with thousands
of atoms involved in various interactions. Their quantum description
cannot be hoped to be solved in reasonable time even using the most
powerful computers.
2.2. Newtonian approach
Classical MD methods — also known as Molecular Mechanics (MM)
— use simple Newtonian equations as reasonable approximations of math-
ematically advanced and resource-consuming quantum mechanics for the
description of the behaviour of biomolecules. All atoms are described as
points with mass, charge, position and velocity which can then be treated
according to the classical laws of mechanics. Atom properties, positions
and charges are used to compute their current potential and subsequently
forces felt by each atom over the course of simulation. Forces acting on
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atoms cause change of their momenta which, when integrated, are used
to update positions and velocities at every step.
2.2.1. Equations of motion
The total mechanical energy of a system can be described by Hamilto-
nian equation as being a sum of the kinetic Ti and potential Vi compon-
ents for all of the particles involved:
H =
∑
i
(Ti(x˙) + Vi(x)) (2.3a)
Ti =
1
2
mix˙
2
i (2.3b)
Vi = Vbonded(xi,xj...) + Vnonbonded(xi,xj...) + . . . (2.3c)
Ti is independent function of momentum for each particle and can be
computed directly. Potential energy (Vi) however, being in principle a
function of all the particles positions is usually only calculated in approx-
imation (see section 2.4). For closed systems total energy is conserved,
hence by comparing its time derivative to zero, one can derive an equation
of system evolution as a form of Newton’s second law of motion:
∂Hi
∂t
= 0 (2.4a)
∂Ti(x˙)
∂t
= −∂Vi(x)
∂t
(2.4b)
mx¨i = −∇Vi(xi,xj...) (2.4c)
The description of particles’ potential energies is, therefore, all that
is theoretically needed to calculate all of a system’s past and future his-
tory given its state (positions and velocities) at any single moment. In
practice, while positions are usually obtained from crystallographic struc-
ture or other similar methods, initial velocities are often randomised to
simulate internal thermal motions.
28
Chapter 2. Methods of Molecular Dynamics
2.2.2. Calculating forces
The potential component of the energy state of a molecular system
is described by a force field, which is a bit misleading name for what is
actually a conservative potential field (scalar field), of which the physical
force field is a gradient (vector field). The actual forces acting on atoms
are calculated during the course of the simulation using the force field
equation, which in its simplest form is a sum of several interactions com-
ponents, sometimes grouped into bonding and nonbonding for clarity:
Vtotal = Vbonded + Vnonbonded (2.5a)
Vbonded = Vbond + Vangle + Vdihedral + . . . (2.5b)
Vnonbonded = VCoulomb + VvdW + . . . (2.5c)
The bonding components are those describing interactions within groups
of atoms connected by covalent chemical bonds(Figure 2.1), while non-
bonding are long-distance interactions (typically electrostatic and Van
der Waals) between any atoms within a model.
the interaction of that atom with the rest of the system. Today, such
force fields present a good compromise between accuracy and
computational efficiency. NAMD employs a common potential
energy function that has the following contributions:
Utotal ! Ubond " Uangle " Udihedral " UvdW " UCoulomb. (2)
The first three terms describe the stretching, bending, and torsional
bonded interactions,
Ubond ! !
bonds i
kibond!ri # r0i"2, (3)
Uangle ! !
angles i
kiangle!$i # $0i"2, (4)
Udihedral ! !
dihedral i
"kidihe#1" cos!ni%i # &i"$, ni ' 0kidihe!0i # &i"2 n! 0, (5)
where bonds counts each covalent bond in the system, angles are
the angles between each pair of covalent bonds sharing a single
atom at the vertex, and dihedral describes atom pairs separated by
exactly three covalent bonds with the central bond subject to the
torsion angle % (Fig. 2). An “improper” dihedral term governing
the geometry of four planar, covalently bonded atoms is also
included as depicted in Figure 2.
The final two terms in eq. (2) describe interactions between
nonbonded atom pairs:
UvdW !!
i
!
j%i
4(ij#$)ijrij%
12
# $)ij
rij
%6&, (6)
UCoulomb !!
i
!
j%i
qiqj
4*(0rij
, (7)
which correspond to the van der Waal’s forces (approximated by
a Lennard–Jones 6–12 potential) and electrostatic interactions,
respectively.
In addition to the intrinsic potential described by the force field,
NAMD also provides the user with the ability to apply external
forces to the system. These forces may be used to guide the system
into configurations of interest, as in steered and interactive MD
(described below).
For every particle in a given context of bonds, the parameters
kibond, r0i, etc., for the interactions given in eqs. (3)–(5) are laid out
in force field parameter files. The determination of these parame-
ters is a significant undertaking generally accomplished through a
combination of empirical techniques and quantum mechanical
calculations;7–9 the force field is then tested for fidelity in repro-
ducing the structural, dynamic, and thermodynamic properties of
small molecules that have been well-characterized experimentally,
as well as for fidelity in reproducing bulk properties. NAMD is
able to use the parameterizations from both CHARMM7 and
AMBER10 force field specifications.
To avoid surface effects at the boundary of the simulated
system, periodic boundary conditions are often used in MD sim-
ulations; the particles are enclosed in a cell that is replicated to
infinity by periodic translations. A particle that leaves the cell on
one side is replaced by a copy entering the cell on the opposite
side, and each particle is subject to the potential from all other
particles in the system including images in the surrounding cells,
thus entirely eliminating surface effects (but not finite-size effects).
Because every cell is an identical copy of all the others, all the
image particles move together and need only be represented once
inside the molecular dynamics code.
However, because the van der Waals and electrostatic interac-
tions [eqs. (6) and (7)] exist between every nonbonded pair of
atoms in the system (including those in neighboring cells) com-
puting the long-range interaction exactly is unfeasible. To perform
this computation in NAMD, the van der Waals interaction is
spatially truncated at a user-specified cutoff distance. For a simu-
lation using periodic boundary conditions, the system periodicity is
exploited to compute the full (nontruncated) electrostatic interac-
tion with minimal additional cost using the particle-mesh Ewald
(PME) method described in the next section.
Full Electrostatic Computation
Ewald summation11 is a description of the long-range electrostatic
interactions for a spatially limited system with periodic boundary
Figure 2. Internal coordinates for bonded interactions: r governs bond
stretching; $ represents the bond angle term; % gives the dihedral
angle; the small out-of-plane angle + is governed by the so-called
“improper” dihedral angle ,.
Scalable Molecular Dynamics with NAMD 1783
Figure 2.1. Simplified scheme of interactions within molecule.
Generalised coordinates labelled: r - the bond length, θ - angle between
subsequent bonds, and φ - dihedral angle between conjugated bonds
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Actual values of energies for each of the parts of the equation are
calculated using predefined set of parameters also called Force field, often
with their own additional non standard terms. Generalised coordinates
in the equations are calculated at each step from actual atom positions.
Finally, all coordinates are used to compute forces according to the force
field equation. The three most commonly used force fields in biochemisty
are Amber[68], Gromos[69] and Charmm[70].
2.2.3. Integration algorithm
Because analytical solutions of system evolution are practically im-
possible for any biochemical system, updating of positions and velocities
is done numerically in discrete steps instead. Given the current position,
velocity and acceleration computed from potential through equation of
motion, the next step of simulation can be approximated by Taylor ex-
pansion:
x(t+ δt) = x(t) + x˙(t)δt+
x¨(t)
2
(δt)2 +O((δt)3) (2.6a)
x˙(t+ δt) = x˙(t) + x¨(t)δt+ . . . (2.6b)
x¨(t+ δt) = x¨(t) +
...
x(t)δt+ . . . (2.6c)
where O(f(x)) is notation for upper bound for absolute value of unknown
or neglected component (error) of function.
This approach has several problems (cumulating errors, low numerical
stability, etc.) which will not be described here in detail. More accurate
methods of integration include the Verlet algorithm which in its basic
form can be derived from the previous one (Equation 2.6a):
x(t+ δt) = x(t) + v(t)δt+
a(t)
2
(δt)2 +
b(t)
6
(δt)3 +O((δt)4) (2.7a)
x(t− δt) = x(t)− v(t)δt+ a(t)
2
(δt)2 − b(t)
6
(δt)3 +O((δt)4) (2.7b)
x(t+ δt) = 2x(t)− x(t− δt) + a(t)(δt)2 +O((δt)4) (2.7c)
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In this form, the Verlet algorithm does not contain an explicit velocity,
which simplifies calculations, but can be a problem in some MD simula-
tions, when velocities are needed to calculate some system properties like
temperature or kinetic energy. This problem is dealt with by calculating
velocities using positions:
v(t) =
x(t+ δt)− x(t− δt)
2δt
+O((δt)2) (2.8)
(note the higher error, which is acceptable as it’s not accumulated), or by
employing more advanced versions of the algorithm (not discussed here).
In all numerical algorithms, the integration error is an increasing func-
tion of timestep. In addition to this, some processes put an upper limit on
timestep — e.g. molecular vibrations frequency of 1012–1014Hz require
timestep of order of 10−15s or 1fs to properly observe their dynamics. On
the other hand too short a timestep will cause longer calculation times
and higher costs without significantly increasing precision.
2.3. Coarse grained simulation
Coarse grained methods are, in a way, the next step of approximation,
found on the opposite side of all-atom molecular dynamics to that of
quantum mechanics. Instead of dealing with single atoms, groups of
atoms are treated together as superatoms.
In the simplest version, only hydrogen atoms are disregarded as separ-
ate particles and treated with heavier atoms, e.g. three atoms of CH2 are
treated as one heavy pseudoatom C2H instead. This method is specifically
called united atom simulation and was used extensively in earlier days of
MD. Its importance as an approximation of all-atoms MD has diminished
over time along side with improvements in computing technology.
For higher level coarse graining, groups of several heavier atoms are
merged into superatoms like PO4
3−, –COOH, 4 H2O etc. In popular
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implementations of this method amino-acids are typically built of 2–5
superatoms each.
In all these method variants, the superatoms have to have their prop-
erties derived from their constituent atoms.
The biggest advantage of this method is the decreased size of model,
which allows larger simulated times and larger systems for lower compu-
tational costs. Coarse grained simulations make it possible to capture
higher level properties and processes like the formation of lipid bilayers.
The price for this is obviously a lower resolution of the results.
2.4. Potential parametrisation
Because of the very large number of potential interactions, it is prac-
tically impossible to construct a force field with universal applicability.
Therefore subsets of possible objects of simulations are chosen as a first
step (e.g. inorganic crystals, proteins, nucleic acids) depending on the
desired subject of research.
A quite common category of problems with existing force fields comes
from the limited subset of parametrised interactions. Many biochemical
structures contain atypical metal ions or inorganic molecules not con-
sidered notable enough to include in expensive parametrisation. These
type of cases necessitate reverting to quantum mechanics (section 2.1)
or other methods to compute the missing parameters before running any
simulations.
Amber force field used throughout research for this thesis is described
by the Equation 2.9. Bonding potential components are expressed in term
of variables for bond lenght r, angle θ and dihedral angle φ with equilib-
rium values req, θeq and γ respectively, and harmonic constants Kr, Kθ
and Vn. Nonbonding interactions contain distances Rij between unbound
atoms, to compute van der Waals interaction (as Lennard-Jones poten-
tial 6–12) and Coulomb interactions (function of partial charges qi, qj),
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with constant parameters Aij and Bij. Because calculating nonbonding
interactions between all pairs of atoms is not practical for large models,
atoms outside of the specified range are cut-off from computation.
V =
∑
bonds
Kr(r − req)2 (2.9a)
+
∑
angles
Kθ(θ − θeq)2 (2.9b)
+
∑
dihedrals
Vn
2
[1 + cos(nφ− γ)] (2.9c)
+
∑
i<j
[
Aij
R12ij
− Bij
R6ij
+
qiqj
Rij
]
(2.9d)
Each term of equation thus includes not only the actual state of
the molecule in generalised coordinates, but also the state of reference
(usually of minimum energy) and scaling constants. Equilibrium val-
ues, as well as other parameters, have to be derived by other means
(e.g. quantum mechanical, experimental, thermodynamical) in a process
called force field parametrisation, for each type of atom, which do not
necessarily map one-to-one to chemical elements, except for the most
simplified models. Typically, equilibrium values come from experiment
and high-level ab initio calculations; the force constants are optimised to
reproduce experimental and high-level ab initio vibrational frequencies of
bonds and energy differences of conformations and rotational profiles[68].
Additional complication of this model comes from introducing different
types of atoms depending on the chemical environment, e.g. aromatic vs
aliphatic carbon. Amber forcefield employs 35 basic atom types, includ-
ing five carbon, eight nitrogen, three oxygen and six hydrogen, as well as
22 special types[68].
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2.5. Statistical methods
2.5.1. Trajectory interpretation
The immediate result of MD simulation is a set of trajectories con-
taining positions and possibly velocities of all atoms over time. The
first analysis may thus be presenting the trajectories in video or tabular
format, but the usefulness of this approach is rather limited. It is more
typical to employ mathematical methods of analysis. The simplest formal
trajectory analyses are computations of statistical properties root mean
square deviation (RMSD) and root mean square fluctuation (RMSF).
In RMSD (Equation 2.10a) the positions of all atoms or their signi-
ficant subset (chosen molecules or types of atoms) are averaged for each
time step and interpreted as a function of time. It is typically used as
an indication of structure stability over time or the equilibration of a
dynamic system.
In RMSF (Equation 2.10b) the same positions are averaged over the
entire simulation time (or notable periods of time) for each atom (or
group of atoms like molecule, residue) separately and interpreted as a
function of atom (molecule, residue, etc). It may be used as a simple
measure of the relative stability of the different parts of the molecule
(e.g. protein domains), among others.
RMSDt =
√√√√ 1
N
N∑
i=1
(
xi(t)− x˜i
)2
(2.10a)
RMSFi =
√√√√ 1
T
T∑
t=1
(
xi(t)− x˜i
)2
(2.10b)
Both functions are completely agnostic of the nature of the system de-
scribed and have applications outside of molecular dynamics, as opposed
to the specifically physicochemical functions described in section 2.6.
While it is perfectly possible to modify the equations e.g. by taking
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the weighted mean of atom masses or charges, this is rarely done, and
this method is only used for crude initial analysis.
2.5.2. Correlation coefficient
Pearson’s correlation coefficient (Equation 2.11) is calculated for two
ordered sets of same cardinality (or equivalently a set of pairs) to test the
null hypothesis. The sets are deemed to be uncorrelated if the coefficient
is not significantly different from zero.
r(X, Y ) =
∑
i (xi − x¯) (yi − y¯)√∑
i(xi − x¯)2
∑
i(yi − y¯)2
(2.11)
2.6. Binding Energy
One of the most important thermodynamic properties of a system
is its free energy. The thermodynamic free energy, or an energy which
can be used to do non-mechanical work, is a state function, defined as a
system’s internal energy less the unusable entropic energy. Depending on
experimental conditions, several different definitions of available energy
are used. It may depend, among others, on temperature (T) and pressure
(p), and indirectly on number (N) of molecules and volume (V) through
gas equation. Biochemical reactions occurring in living organisms are
usually interpreted in isothermal-isobaric (NPT) ensemble, with constant
total number (N) of molecules, but also temperature (T) and pressure
(p).
Gas equation pV = nRT (2.12a)
Internal energy U(S, V ) (2.12b)
Enthalpy H(S, p) = U + pV (2.12c)
Helmholtz free energy A(T, V ) = U − TS (2.12d)
Gibbs free energy G(T, p) = H − TS = U + pV − TS (2.12e)
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Free energy is a very useful concept for analysing reactions. The
system’s free energy is at a minimum when the system reaches equilib-
rium state. It is therefore convenient to use the difference in free energy
between states as a criterion for spontaneous reactions. In this work
the term “free energy” will henceforth imply Gibbs free energy (Equa-
tion 2.12e).
We define binding energy as follows:
∆G = Gcomplex − (Gprotein +Gligand) (2.13)
Direct measurement of free energy is a non-trivial task and advanced
methods are employed to achieve that. Advanced methods like Free
energy perturbation (FEP) or Thermodynamic integration (TI) will not
be discussed here in detail. Their accuracy comes at very high computa-
tional price. The focus will be put on approximate methods of determ-
ining free energy instead.
2.6.1. Continuum solvation methods
Two similar methods of molecular mechanics Poisson–Boltzmann sur-
face accessibility (MM-PBSA) and molecular mechanics generalised Born
surface accessibility (MM-GBSA) calculate binding free energies for mac-
romolecules by combining molecular mechanics calculations and con-
tinuum solvation models[71]. Unlike more expensive exact methods, they
can be used to calculate free energies from a single run of a receptor
with ligand(s) in a complex, decreasing the cost of simulation at least
threefold. Also, unlike more complex methods, they only require running
a simulation of the immediate neighbourhood of the final (bound) state.
In practice, a larger number of simulations (replicas) is run simul-
taneously (the so called ensemble approach) instead of one very long
simulation to achieve better coverage of the immediate neighbourhood in
a states’ phase space. Although MD itself is perfectly deterministic, both
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thermostats and barostats used in simulations are usually stochastic,
providing required variance between replicas.
The method involves running molecular dynamics simulations for
bound complex in water solution with the total charge neutralised by
counterions. Collected trajectories are then postprocessed by removing
solvent together with the counterions, and calculating the energy com-
ponents:
〈G〉 = 〈EMM〉+ 〈Gsol〉 − TSMM (2.14a)
〈Gsol〉 =
〈
GPB/GB
〉
+ 〈GSA〉 (2.14b)
〈EMM〉 = 〈Ebonding〉+ 〈EvdW 〉+ 〈Ecoulomb〉 (2.14c)
where an electrostatic (polar) component GPB/GB of solvation energy is
calculated using the Poisson-Boltzmann or Generalised Born equation
respectively, and nonpolar GSA is estimated by solvent accessible surface
area. TSMM is the solute entropy, which can be estimated by quasi
harmonic or normal-mode analysis, but it is often ignored due to its
high computational cost, compared to relatively low contribution to total
energy[72].
By substituting G from Equation 2.14a in Equation 2.13 bonding
components cancel out, the entropic component being very small in com-
parison is therefore ignored, thus giving the final equation:
∆G = ∆ 〈Gsol〉+ ∆ 〈EvdW 〉+ ∆ 〈Ecoulomb〉 (2.15)
MM-PBSA
The MM-PBSA method of calculating binding energy is an approxim-
ate method that has been proven successful in free energy calculations in
large number of experiments. With relatively good coverage of a system
states’ phase space, reasonably accurate results can be obtained.[72].
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MM-GBSA
The MM-GBSA method is very similar to the previous one. The only
difference is in calculating polar component of solvation energy by Gen-
eralized Born equation (GGB). The comparisons between both methods
are numerous and inconclusive. The MMGBSA is generally accepted as
underperforming in calculating absolute binding free energies, compared
to MM-PBSA[71]. It is nevertheless used extensively because of its lower
computational cost and decomposability. Binding energy per residue
decomposition is often essential in identifying structural determinants of
the binding affinity[73].
2.7. Thermodynamic view of binding affinity
As elaborated earlier, RLT is the Integrase inhibitor binding the act-
ive site competitively to DNA which would otherwise be integrated dur-
ing the strand transfer phase of HIV lifecycle.
This work is not in any measure extensive research on thermody-
namics, but some basic concepts will have to be introduced for easier
reception of the motivations and results of this project.
Most biological processes, including HIV strand transfer catalysed by
Integrase, are on a basic level chemical reactions between large molecules.
The enzyme A (Integrase) binds its ligand B (DNA) non-covalently in a
reversible reaction before performing the actual enzymatic reaction.
A+B
ka−−⇀↽−
kd
AB
ke−−→ A+B∗ (2.16a)
Ka =
1
Kd
=
ka
kd
=
[AB]eq
[A]eq[B]eq
(2.16b)
where ka and kd are rate (kinetic) constants of association and dissoci-
ation respectively, ke is rate constant of essentially irreversible enzymatic
reaction, Ka and Kd are equilibrium constants defined by equilibrium
concentration [AB]eq, [A]eq and [B]eq. This very simplified picture ig-
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nores the complexity of catalysed enzymatic reaction step, to focus on
the first step only, which is the target of the inhibitor. The competitive
inhibitor is an alternative ligand which, when binding to the enzyme
blocks (inhibits) the enzymatic reaction. The inhibitor may exist in a
natural system as part of physiological pathway or in the case of most
drugs be engineered to maximise the binding affinity and subsequently
the efficacy. The exact mechanism of inhibition may vary tremendously,
and in the case of HIV Integrase inhibitors is not fully explained, but the
effects on system dynamics may be approximated by equations analogous
to Equation 2.16a and Equation 2.16b:
A+B + I
ki−−⇀↽−
kj
AI +B (2.17a)
Ki =
ki
kj
=
[AI]eq[B]eq
[A]eq[I]eq[B]eq
(2.17b)
where Ki is inhibition equilibrium constant measured at equilibrium con-
centration of enzyme-inhibitor complex ([AI]eq), free enzyme ([A]eq) and
free inhibitor ([I]eq). The concentration of a ligand ([B]eq) which does
not participate in the reaction cancels out.
Combining Equation 2.16b and Equation 2.17b by solving and sub-
stituting concentration of free enzyme — which is in equilibrium with
both complexes — gives a ratio of a protein bound to ligand (involved in
a first step of enzymatic reaction) to inhibited protein as a function of
both thermodynamic constants and concentrations of competing ligands:
[AB]eq
[AI]eq
=
Ka[B]eq
Ki[I]eq
(2.18)
Equilibrium constant is related to Gibbs binding free energy intro-
duced in section 2.6 through reaction isotherm equation:
∆G = −RT ln(Ka) (2.19)
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Finally, the thermodynamic constant from Equation 2.19 can be sub-
stituted into Equation 2.18 giving the ratio of inhibited protein in terms
of free energy levels of involved states.
[AB]eq
[AI]eq
=
[B]eq
[I]eq
exp
(
−∆GB −∆GI
RT
)
(2.20)
The Equation 2.20 shows the relation between binding energies ∆GI
calculated throughout this project and the inhibition efficiency of a drug.
The subscript I is conveniently omitted throughout the rest of this thesis
but it is clear from the context when calculated values of ∆G refer to
∆GI , where complex of In with RLT is analysed. The complex of In-
tegrase with inhibitor showing lower (more negative) ∆GI means less In
bound to DNA, or more effective inhibition. Conversely, higher (less neg-
ative) ∆GI means less effective inhibition or more resistant viral enzyme.
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integrase
In this chapter I will describe the attempts to obtain a structure of
HIV IN by the methods of Homology Modelling. As one of the desired
structure purposes is further MD experiments, a high resolution all-atom
structure is required, hopefully of a complete protein complex with the
drug and the DNA attached, to simulate the natural process of DNA
binding inhibition by the drug.
3.1. Introduction
Homology modelling is one of the methods used for detailed prediction
of protein structures which cannot be obtained by experimental methods
directly. Is is based on the fact that all proteins are coded by genes
which are often closely related. The closer the evolutionary relationship
between the protein coding genes – the more similar the protein struc-
ture and function likely are. By using several homologous proteins as
structure templates one may be able to predict the unknown structure
with reasonable precision.
3.1.1. Proteins structure
Protein molecules consist of one or more polypeptide chain built of
amino acids residues by peptide bond (Figure 3.1), and often but not
necessarily other atoms and molecules (ligands) including metal ions,
water molecules, acid residues (phosphates, sulphates, etc.) and others.
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Most enzymes’ functionality involves binding and releasing the ligands
in the catalysed processes which adds another level of complexity.
Figure 3.1. The Peptide bond is a type of amide bond formed between
carboxylic group of first amino acid and amine group of second one.
Amino acid sidechains are replaced with symbols R and R’ respectively
for simplicity.
There are 20 standard biological amino acids and a number of specific
amino acids modified in post-translation process. All amino acids have
the same basic formula NH2−Cα(R)−COOH where R denotes a residue
side chain, with the exception of proline which side chain form a het-
erocycle including both Cα and −NH− as well as three −CH2− groups.
While all amino acids are different from each other in some respect or
another they can be classified in several subcategories by their various
physicochemical properties.
Primary structure is the sequence of amino acid residues in a peptide
chain. It is usually described by listing the one letter codes for amino acid
residues starting from N-terminus (amino acid with free −NH2/−NH3+
group) up to C-terminus (amino acid with free −COOH/−COO− group)
i.e. the order it is assembled in vivo. The primary structure can be easily
discovered by sequencing the protein gene or the protein molecule itself.
Both these methods have been used routinely for some time now.
Changing one amino acid for another in a protein sequence may have
effects ranging from complete loss of protein function to completely neg-
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ligible, depending among other factors on preservation of amino acid
properties.
Secondary structure is the first level of three-dimensional organisa-
tion of protein molecule. The most characteristic secondary structures
are α-helix and β-sheet suggested for the first time by Astbury[74] and de-
scribed in detail by Pauling[75]. In the α-helix backbone CO groups form
hydrogen bonds with groups NH four residues further. In the β-sheet the
hydrogen bonds are formed between backbone groups in parallel or anti-
parallel chains. There are other known secondary structures and most
proteins also possess regions of no particular secondary structure.
Tertiary structure is the name given for high order three-dimensional
molecule organisation. Helices and sheets, as well as coils and unordered
chains fold into compact molecule (Figure 3.2). By bringing distant
Figure 3.2. Protein structure on example of SIV IN. Typically protein
sidechains are omitted and backbone chain is shown schematically as
solid spirals (α-helix shown in red), arrows (β-sheet in yellow) or strings
(sections lacking secondary structure, in green). The image shows higher
level of structure by depicting two protein molecules of two domains each.
parts of the molecule together an active site may be formed and give
the molecule ability to perform its function. The process of folding is
the “Holy Grail” of computational structural biochemistry. It has been
shown that any random process of looking for optimal conformation as
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well as systematic search of whole conformations space would take much
longer than the age of the universe, even for simple proteins[76]. Thus
only some heuristic methods of predicting protein folding are known and
they are far from successful.
Ternary or Quaternary structure names are given to higher orders
of arrangement; depending on context it may mean a spatial relation-
ship between domains of one molecule or of molecules constituting an
oligomer.
3.1.2. Structure determination
The most popular method of determining biomolecules structures de-
posited in Protein Data Bank are —in decreasing order— X-ray crystallo-
graphy, Nuclear Magnetic Resonance and Electron Microscopy (Table 3.1).
Method Proteins Nucleic Acids Prot+NA Other Total
X-ray 58 735 1 268 2 844 18 62 865
NMR 7 709 943 169 7 8 828
EM 250 22 92 0 364
hybrid 28 3 1 1 33
other 132 4 5 13 154
total 66 854 2 240 3 111 39 72 244
Table 3.1. PDB structures breakdown by methods and type of molecule
—as of 5 Apr 2011— according to RCSB[77].
Each of the methods has its advantages and disadvantages, but many
protein structures have eluded determination by any of them for years.
In these cases theoretical methods are employed to predict instead of
determine the structure.
3.1.3. Phylogenetics
One of first steps required for successful homology modelling is es-
tablishing degree of homology between available structures. The most
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closely related homologue structures will subsequently be used in the
modelling.
Protein homology may be result of either a speciation (orthology) or
a gene duplication within organism (paralogy), but in case of viruses the
latter in very unlikely thus the term homology will subsequently imply
orthology or relationship between proteins and genes from related species.
It is generally agreed that the closer the homologue the better it serves
as modelling template. To that end the relationships between known
structures is analysed using phylogenetic analysis. Unrelated proteins
often share some structural and/or functional properties e.g. due to evol-
utionary convergence but they are usually useless as modelling templates
because their similarities are superficial. Different strains of HIV, e.g. had
been reported to convergently evolve nuclear receptor-responsive element
(NRRE) in the LTR region[78]. On the other hand closely homologous
protein with unrelated function may still share fundamental structural
priorities with the protein of interest and be useful as a template.
During the course of evolution protein sequences change through point
mutations of genetic code. Due to redundant nature of the code many
mutations don’t affect the expressions at all, mutation in 3rd nucleotide
of a codon has high chance of preserving encoded amino acid. Of those
mutations that do replace one amino acid with another not all have
measurable effect on protein properties thanks to the fact that similar
codons often encode amino acids with similar properties.
Amino acids share many properties between them and thus replacing
one with very similar may in fact have negligible effects. Similarly, change
in relatively unimportant region of a protein, far from active centre may
have no effect on its function at all unless it causes structural change or is
responsible for essential interaction with environment. Such neutral point
mutations, while meaningless for the organism’s biochemistry are useful
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in research of genealogical relationships between species and individuals,
because they are not subject to evolutionary selection.
On the other hand mutation may have dramatic effect if changed
amino acid had performed catalytic or important structural role. Typ-
ical examples include Sickle-cell anæmia caused by mutation E6V in
β-globin gene (meaning sixth position in a sequence, normally occupied
by Glutamic Acid is replaced with hyrophobic Valine, changing overall
protein shape and affecting its function as a result) or Hæmochromatosis
(H63D or C282Y in HFE gene[80][81]).
Some mutations can be potentially beneficial to their carriers e.g. by
improving enzyme efficiency, providing better protection from diseases,
new functionality. In case of protein being drug targets, mutation may
reduce drug efficiency by changing binding site structure, change bene-
ficial for targeted organism but detrimental for therapy prognosis for a
patient.
The immediate goal behind phylogenetic analysis of a group of related
sequences is to infer a degree of relationship between them, then usually
presented in form of binary tree. The phylogenetic tree represents the
evolutionary history of a group where bifurcations represent speciacion or
gene duplication events. Most methods also allow estimation of relative
degree of divergence which —with sufficient temporal data from other
methods like history or palæontology— may be used to estimate dates
of all bifurcation events.
Successful analysis requires fulfilling several conditions:
— Evolutionary events are strictly bifurcating with no horizontal trans-
fers
— Each position in sequence evolved homogeneously and independently
— The sequences are correct and from specific sources
— The sequences are actually closely related
— The sampling data is sufficient and adequate
46
Chapter 3. Homology Modelling of HIV integrase
Two first conditions are completely independent from the researcher
and are rather assumptions about the subject of research. The conditions
on input data, while often hard to verify beforehand can be improved
through additional research and more hands-on iterative analysis. De-
tailed initial analysis may in particular show insufficiency of data, lack
of identifiable relationship between some sequences or even hint at con-
vergent evolution. In these cases revision of input set is required.
3.2. Methods and tools
3.2.1. Sequence alignment and Clustering
A systematic analysis of relationship was attempted for HIV-1 IN
and several homologous proteins for which structures had already been
solved — HIV-2 (3F9K), SIV (1C6V), MVV (3HPG), RSV (1C0M), ASV
(1CXQ) and PFV (3L2Q) — as found in Protein Data Bank (PDB), with
their respective PDB codes in parentheses. The names and structures
behind these acronyms will be revealed in section 3.3. The genealogical
relationship was reconstructed by the progressive sequence alignment
analysis with the ClustalW tool[82]. Progressive, or hierarchical align-
ment method combines clustering and multiple sequence alignment into
an iterative process during which a guiding tree is constructed using de-
fault Neighbour Joining method[83], producing an annotated alignment.
The graphical representation of phylogenetic tree was generated with the
program Archæopteryx[84] from the annotated alignment.
3.2.2. Modelling
Having obtained a phylogenetic tree with sequence alignment the next
step is to use this information to predict the structure of the protein in
question. The modelling relies on the assumptions that protein struc-
ture is determined by a sequence, hence similar sequences yield similar
structures. Known protein structures defined by aligned sequences are
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therefore aligned in space in a way that minimises distances between
homologous amino acid residues. At this stage some proteins may turn
out not to preserve the structure of their homologues and may need to
be discarded. Aligned structures are then used as a three-dimensional
template for the sought structure, while phylogenetic distances may be
used as weights in dubious sections.
Swiss-PdbViewer —also known as DeepView— is one of the most
popular tools for structural bioinformatics[85]. It provides an integrated
sequence to structure analysis and modelling platform[86]. DeepView
was used for structural alignment of overlapping protein fragments, in-
troducing mutations, filling short gaps (“loop building”) and other model
building tasks, as well as parallel orientation of structures for visualisa-
tion purposes and short energy minimisation using built-in Gromos96
force-field.
Modeller software[87] is designed for minimal researcher intervention
which puts it in the category of “Black Box” tools. In the simplest
case providing template structures and sequence alignment is enough to
generate a model. However, further modifications and optimisations are
usually required to obtain useful structures. Because of the “Black Box”
nature of the process it is difficult to evaluate the final model without
comparing it to the real structure, which is usually unknown at this stage.
It may, however, be combined with other data, e.g. as a template for
Molecular Replacement method for x-ray crystallographic experiment.
3.3. Input data
No complete structure of HIV IN, with or without substrates, is
known as of today. Unfortunately, all attempts to crystallise HIV-1 IN
turned out to be unsuccessful. Similarly structure determination by the
method of NMR is thwarted by low solubility of IN. However, several
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homologous proteins, as well as partial structures have been solved. All
protein molecules henceforth are visualised with PyMol molecular viewer,
render tool, and 3D molecular editor[88]. Where appropriate, PDB struc-
ture of visualised molecule is indicated by its four-character code.
3.3.1. HIV-1 Integrase Homologues
Some lentiviruses had already been researched even before HIV dis-
covery. Several structures homologous to HIV-1 IN have been solved
and deposited in PDB giving insight into the common features of the
lentiviral integrases family. As all those structures have a potential use
in homology modelling the review of available data is presented below.
ASV integrase
Figure 3.3. ASV Integrase, PDB:1CXQ
The crystallisation of Avian Sarcoma Virus (ASV) integrase CCD
(residues 52–198) monomer under a range of conditions had shown the
high flexibility of active-site loop 144–154 (homologous with HIV-1 loop
138–148), suggesting functional conformational changes depending strongly
on pH[89]. The structure of ASV IN is shown in Figure 3.3.
RSV integrase
Following the research showing that two out of three domains (CCD
and CTD) of RSV together are able to perform terminal cleavage and
strand transfer[90] the crystallographic structures of RSV IN (res 49–286)
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Figure 3.4. RSV Integrase, PDB:1C0M
and its mutants were solved[91]. Notably, only slightly shorter RSV
IN (58–286) had shown no correct activity. Despite not being directly
involved in active site ions binding, the missing segment (49–57) is close
enough to it to affect the process, and it lies in the probable DNA binding
surface. The structure is shown in Figure 3.4.
SIV integrase
Figure 3.5. SIV Integrase, PDB:1C6V
The structure of two-domain SIV IN even closer HIV IN homologue
confirmed the CCD and CTD structure, as well as the domains relative
position[92]. At the time only single domains of HIV IN were solved,
thus the structure of such a close homologue was an important indica-
tion of a DNA binding site along both domains. The structure shows
the asymmetric dimer of dimers as indicated for active form by earlier
works[93]. See the structure of a dimer in Figure 3.5.
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MVV integrase
Figure 3.6. MVV Integrase, PDB:3HPG
Two-domain Maedi-Visna Virus (MVV) (4–212) structure with its
cofactor Lens epithelium-derived growth factor (LEDGF) shows possible
tetrameric configuration of active complex[94]. The structure of a single
dimer is shown for comparison in Figure 3.6.
HIV-2 integrase
Figure 3.7. HIV-2 Integrase, PDB:3F9K
The structure of NTD and CCD HIV-2 IN domains (1–207) with
LEDGF sheds further light on the question of charge based interactions
between the constituents of active complex[95]. The structural and func-
tional similarity between HIV-1 and its closest homologue HIV-2 have
been confirmed by engineering HIV-1 mutant with increased affinity to
LEDGF Integrase Binding Domain (IBD) using HIV-2 structure. The
structure of HIV-2 IN dimer is shown in Figure 3.7.
51
Chapter 3. Homology Modelling of HIV integrase
PFV integrase
Figure 3.8. PFV Integrase, PDB:3L2Q
The first structure of integrase complete intasome shows complete
PFV IN molecule interacting with 19-bp (base pairs) DNA[96]. The
DNA seems to be coupled tightly with IN active site, with the 5’end 3-bp
(ATT) heavily distorted from its native conformation and separated from
its complementary 3’end A – remaining two bp being already cleaved out.
Both N-term domain stabilising Zn–HHCC and core Mg–DDE motifs
are present, although due to poor resolution Glu221 does not seem to
take part in chelating Mg. Instead, the structure with Mn shows more
unambiguous complex of two Mn ions with D,D(35)E. The Mn/Mg ions
in the complex are homologous to the Cd/Zn in ASV, illustrating the
consistent organisation of active site regardless of type of ion.
The structures of IN intasome with drugs MK0518 (RLT and GS9137
(ELV) were solved in the same set of experiments. The drugs seem to fit
well within the active site and not only interact with metal–DDE complex
but also bind and displace the DNA 3’end A, possibly explaining the
mechanism of inhibition.
The significance of experimental data regarding IN intasome is countered
by the fact that PFV is the most distant homologue of HIV-1, out of sev-
eral reviewed in this work. Although the active site is very well conserved
among all of them, the PFV IN overall high-level conformation, highly
dependent on the domains internal structure is notably different. The
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exact mechanism of DNA binding by HIV-1 is thus still a matter for fu-
ture research. The usability of PFV IN intasome structure in simulating
HIV-1 IN intasome model dynamics still needs to be determined.
Summary
The catalytic core domain is clearly very well conserved among all
homologues. The structure of the active site seems not to be significatly
affected by mutations introduced to increase solubility and/or crystallisa-
tion. The remaining domains show more variation in both sequence and
structure (when it is known). Nevertheless, all data gathered through
research on HIV-1 IN homologues contributes to the general knowledge
of Integrases structure and function.
3.3.2. HIV-1 Integrase partial structures
Although complete HIV-1 structure has not been crystallised yet,
several partial structures have been solved instead. Partial structures,
especially when combined with complete homologues are valuable as an
input for homology modelling.
Core domain
Figure 3.9. HIV Integrase core domain, PDB:1QS4
The first structure of HIV-1 IN core domain (55–209) was solved in
1994 (pdb entry 1ITG)[97], followed by solution of active site binding Mg
ions in ASV-IN (1ASU, 1ASV, 1ASW)[98] and HIV1-IN (1BH2, 1BI4)[99]
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which confirmed the high level of similarity between family members, at
least in respect to the active site, specifically D,D(35)E motif. Finally
the structure of core domain with bound inhibitor was solved in 1999
(1QS4)[100].
Core and C-term domains
Figure 3.10. HIV Integrase CCD and CTD, PDB:1EX4
The first multidomain structure of HIV-1 IN, solved in 1999, was of
a five point mutant core and C-term domains (56–270) [101]. A short
segment of core domain is missing (142–144) from the pdb structure.
The structure shows a Y-shape dimer. Core domains form surface in-
teraction between molecules while C-term domains remain 55A˚ apart.
The dimerisation through core domain shows similarity to both RSV[91]
and SIV[92] integrases which suggests it will also be found in full-length
IN[101].
The relative arrangements of domains, however, differs significantly
between homologues, suggesting flexibility. The link between core and
C-term domains of HIV IN shows some flexibility around T210 and in-
troduces asymmetry to the dimer by 90◦ rotation of one of the C-term
domains[101].
A contiguous strip of positive charge along the outside surface of the
dimer suggests the binding path for DNA[101].
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Figure 3.11. HIV Integrase NTD and CCD, PDB:1K6Y
N-term and core domains
A structure of N-term and core domains confirms the dimeric struc-
ture again[102]. The direct interaction between respective CCDs is found
again, except the slight difference of one loop (188–194) on the interdo-
main interface. The link between domains (47–55) is missing, as well as
part of the core domain (140–148).
The N-term domains are stabilised by one Zn ion each, chelated by
His12, His16, Cys40, Cys43 (HHCC motif). The relative spatial orienta-
tion of N-term domains in the two domains structure differs significantly
from that of isolated domains due to the arrangement of core domain
and interdomain link[102].
Once again asymmetry is introduced by interdomain link causing one
of N-domains to be moved by 15◦ in relation to core domain[102].
The phosphate anion identified 7A˚ from away the active site is sug-
gesting the binding site of DNA backbone[102].
The crystal structure shows higher order dimer-of-dimers which would
confirm earlier suggestions that IN acts as a tetramer in vivo. Although
the tetramer of HIV IN NTD–CCD protein was not observed in solution,
only in crystal[102], the CCD–CTD protein tetramerises in solution as
well[103] indicating a role of C-term domain in tetramerisation. It has
also been pointed out that superimposing partial complementary struc-
tures of HIV-IN tetramer does not introduce any significant steric clashes
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and shows some similarity to Tn5 transposase[102] leaving the possibil-
ity of DNA binding similar to that of Tn5[104]. The shape of the groove
would require bending of DNA for integration, which is consistent with
earlier findings[105][106][107].
3.3.3. Theoretical models
Several documented attempts have been made to determine HIV-1
IN by the means of theoretical methods. Although the generation of
a feasible protein model by superimposing known partial structure is
pretty straightforward[102], with only a few residues left to modelling,
the actual problem is the binding site of DNA.
The first attempts involved manual docking of DNA into the protein[108][109]
or protein–drug complex[110].
Anther approach involves automatic docking of DNA using a modi-
fied version of ESCHER program[111], normally used for protein–protein
interactions.
3.4. Results
In this chapter will be described attempts to generate a plausible
model of HIV-1 IN based on existing partial and homologous structures.
With an actual structure unavailable or incomplete, homology modelling
may provide a viable alternative. Unfortunately, without high quality
structures of close homologues the quality of model may turn out not to
be satisfactory for the purpose of MD simulations. However, even if not
sufficient for detailed quantitative analyses, it may still be proven useful
for qualitative insight into the working of the protein.
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3.4.1. Sequence alignment
The genealogical relationship was reconstructed by multiple sequence
alignment analysis with the ClustalW[82] command line tool. The align-
ment of the most conserved region is shown in Table 3.2.
Species pdb res- sequence -res
HIV-1 — 55 .DCSPGIWQLDCT..HLEGK VILVAVHVASGYIEAEVIPA 91
HIV-2 3F9K 55 .NAELGTWQMDCT..HLEGK IIIVAVHVASGFIEAEVIPQ 91
SIV 1C6V 55 .NSDLGTWQMDCT..HLEGK IVIVAVHVASGFIEAEVIPQ 91
MVV 3HPG 47 .KRGIDHWQVDYT..HYEDK IILVWVETNSGLIYAERVKG 93
RSV 1C0M 55 .LGPLQIWQTDFT..LEPRM APRSWLAVTVDTASSAIVVT 91
ASV 1CXQ 55 .LGPLQIWQTDFT..LEPRM APRSWLAVTVDTASSAIVVT 91
PFV 3L2Q 118 PQKPFDKFFIDYIGPLPPSQ GYLYVLVVVDGMTGFTWLYP 157
alignment .......+..*......... .....+.:..:......+..
HIV-1 — 92 ETGQET.....AYFLLKLAG RWPVKTIHTDNGSNFTGATV 126
HIV-2 3F9K 92 ESGRQT.....ALFLLKLAS RWPITHLHTDNGANFTSQEV 126
SIV 1C6V 92 ETGRQT.....ALFLLKLAG RWPITHLHTDNGANFASQEV 126
MVV 3HPG 94 ETGQEFR.....VQTMKWYA MFAPKSLQSDNGPAFVAEST 128
RSV 1C0M 92 QHGRVTSVAVQHHWATAIAV LGRPKAIKTDNGSCFTSKST 131
ASV 1CXQ 92 QHGRVTSVAAQHHWATAIAV LGRPKAIKTDNGSCFTSKST 131
PFV 3L2Q 158 TKAPSTS..ATVKSLNVLTS IAIPKVIHSDQGAAFTSSTF 195
alignment ..:................. ....:.+++*+*:.*::...
HIV-1 — 127 RAACWWAGIKQEFGIPYNPQ SQGVVESMNKELKKIIGQVR 166
HIV-2 3F9K 127 KMVAWWIGIEQSFGVPYNPQ SQGVVEAMNHHLKNQISRIR 166
SIV 1C6V 127 KMVAWWAGIEHTFGVPYNPQ SQGVVEAMNHHLKNQIDRIR 166
MVV 3HPG 129 QLLMKYLGIEHTTGIPWNPQ SQALVERTHQTLKNTLEKLI 168
RSV 1C0M 132 REWLARWGIAHTTGIPGNSQ GQAMVERANRLLKDRIRVLA 171
ASV 1CXQ 132 REWLARWGIAHTTGIPGNSQ GQAMVERANRLLKDKIRVLA 171
PFV 3L2Q 196 AEWAKERGIHLEFSTPYHPQ SSGKVERKNSDIKRLLTKLL 235
alignment .......**....:.*.+:* :::.**..+..+*..+..+.
Table 3.2. Multiple sequence alignment of most conserved region of len-
tiviral integrases. Active centre D,D(35)E motif residues are shown in red
(see subsection 1.4.3). Standard ClustalW scheme for results display -
an asterisk (*) denotes residue conserved among all compared sequences,
plus (+) and colon (:) indicate decreasing conservation, and dot (.) the
remaining residues with insufficient similarity.
3.4.2. Phylogenetics
The phylogenetic tree was built with the program Archæopteryx[84]
on the previously generated alignment. The approximate genealogical
relationship between proteins inferred from their sequences is shown in
the Figure 3.12.
57
Chapter 3. Homology Modelling of HIV integrase
0.06
0.13
0.21 HIV-1
0.07
0.16 SIV
0.15 HIV-2
0.36 MVV
0.37
RSV
0.45 PFV
0.06
0.0   ASV
Figure 3.12. Phylogenetic tree of lentiviral integrases. Branch lengths
proportional to amount of inferred evolutionary change between nodes
and their ancestors. Branch labels describe ratio of change in relation to
whole integrase sequence.
3.4.3. Modeller
The Modeller software tool[87] was used for model generation, using a
previously generated sequence alignment with different sets of templates
chosen from HIV-1 structures (1K6Y, 1EX4, 1WJA) and complete ho-
mologous PFV intasome (3L2Q). While closer homologues exist, their
structures —being incomplete— do not bring much additional informa-
tion required for model building. Tertiary structure of the molecule is
quite consistent between all generated models, nevertheless the variance
between structures are too big to ignore, decreasing confidence in their
value as foundation for further research.
3.4.4. Initial model
The initial mock models of HIV Integrase were generated using three
partial HIV-1 structures (1K6Y-A, 1EX4-A, 1WJA-A) and complete ho-
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mologous PFV intasome (3L2Q-A). The model did not show any unusual
features, thus encouraging taking a more advanced approach using the
same technique.
3.4.5. Monomeric apoprotein molecule
The template for IN model was manually generated by superimposing
1K6Y-B and 1EX4-A core domains over 1QS4-B and then merging seg-
ments from all chains to obtain an almost complete template. There were
still gaps in positions 47–55 (between NTD and CCD), 142 (in CCD) and
271–288 (the final segment of CTD).
HIV-1 IN sequence were used to replace mutated residues from the
template with wild type residues. Some sidechains exhibited high energy
due to interactions with reintroduced sidechains. They were manually
reorientated before further optimisation. Missing residues were reintro-
duced to the structure by DeepView Loop Builder and the complete
model energy was minimised. The resulting model of apomonomer is
shown in Figure 3.13.
3.4.6. Modelling the dimer
Initially the dimer was modelled by superimposing the same generated
monomer over both respective structures from 1QS4. There were areas
of high energy interactions between molecules which were eliminated by
simple minimisation. Figure 3.14 shows the dimer constructed from the
identical monomers.
In the next approach the asymmetric dimer was built starting from
1QS4 using respective structures from 1K6Y and 1EX4. The difference
in energy between symmetric and asymmetric structures were not sig-
nificant at this stage, but it has to be noted that the substrate (DNA)
is probably the stabilising factor of asymmetric structure. The resulting
model is shown in Figure 3.15.
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Figure 3.13. Single apoprotein model generated with DeepView by su-
perimposing matching parts of 1EX4-A and 1K6Y-B core domains over
1QS4-B.
Figure 3.14. Symmetric dimer model generated with DeepView by su-
perimposing two copies of previous model over 1QS4 dimeric structure.
Figure 3.15. Asymmetric dimer model generated with DeepView by su-
perimposing matching parts of 1EX4 and 1K6Y core domains dimers
over respective 1QS4 structures.
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3.4.7. Challenges
While obtained dimeric apoprotein model is in agreement with other
suggested structures, binding DNA and metallic ions lacks consistent
support in literature ([108], [109], [110], [111]). Without a high confid-
ence active centre model no quantitative description of drug binding is
possible.
3.4.8. Conclusions
It has been decided to focus further research on well described crystal-
lographic structures of homologous proteins instead of homology models
of inconclusive reliability. Although the modelling of protein seems to
provide reliable results the problem of docking DNA remains. The most
difficult task, of modelling the DNA interaction with the IN active site
cannot be dealt automatically by any software. With only one intasome
structure available there is not enough data for generalisation. However,
as the active site proves to be very well conserved among all homologues it
is suggested that the drug binding mechanism may be properly described
with satisfying accuracy basing on homologous structures.
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4. PFV Integrase intasome binding
energy in MD
As noted earlier, no complete crystal structure of HIV Integrase is cur-
rently available. However, several structures of Prototype Foamy Virus
(PFV) intasome are solved with different ligands.
This chapter will describe the application of Molecular Dynamics
(MD) to the original complete PFV Integrase (IN) intasome monomer
structure and the subsequent computation of binding energies using the
molecular mechanics Poisson–Boltzmann surface accessibility (MM-PBSA)
and molecular mechanics generalised Born surface accessibility (MM-GBSA)
methods to verify its usefulness as input data for calculations of drug
binding energies in an attempt to explain strand transfer inhibition by
Raltegravir (RLT). PFV Integrase intasome structure[96] (PDB:3L2T,
as shown in Figure 4.1) with RLT in its active centre was chosen for all
simulations as the most complete system available.
The structure contains a fragment of double-stranded DNA helix
which in vivo would be the end of a longer HIV DNA to be integrated
into the host genome. To emulate the restrained movement of such a
configuration parts of DNA in this structure have had their movement
restricted by applying harmonic constraints in some of the simulations.
In the input data, the protein molecule is bound with a DNA double
helix, two magnesium ions and one RLT molecule in active centre (shown
in Figure 4.2). One zinc ion is permanently bound by NTD as well,
contibuting to its structure. The active site contains one copy of RLT,
Integrase strand transfer inhibitor (INSTI) in a position indicating the
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Figure 4.1. Complete structure of monomeric unit of PFV intasome
with inhibitor (PDB:3L2T). Parts marked by colours — NTD (green),
CCD (yellow), CTD (orange), DNA (red), RLT (magenta), Mg (light
blue), Zn (white, in NTD shade).
competitive binding, displacing CAOH-3’ dinucleotide. The structure of
RLT alone is shown in Figure 4.3.
4.1. Methods
The Amber force field, described in chapter 2, was chosen for all
simulations, as it is known for relatively good support for nucleic acid
molecules, without compromising its overall performance for proteins.
4.1.1. Input data and Simulation parameters
Raltegravir
RLT molecule charge was confirmed to be neutral by protonation
state analysis using Protonation bundle of ChemAxon’s Physico-chemical
property predictors Calculator Plugin[112]. Gaussian 03 was used to per-
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Figure 4.2. Active centre structure of PFV intasome with inhibitor.
Parts marked by colours — NTD (green), CCD (yellow), CTD (orange),
DNA (red), RLT (magenta), Mg (light blue). RLT is shown competitively
binding IN active centre, inhibiting DNA binding.
Figure 4.3. Structure of Raltegravir.
form geometric optimisation of the drug molecule using the Hartree–Fock
method. Partial atomic charges were generated with the Restrained Elec-
trostatic Potential (RESP) procedure. Antechamber toolkit was used to
complete forcefield parametrisation of the drug in General Amber Force-
field (GAFF)[68].
Forcefield
Amber standard ff03.r1 forcefield was used to parametrise the Integ-
rase receptor consisting of a protein molecule and double DNA helix[113].
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The Zn2+ ion chelated by the tetrahedral HHCC motif (subsection 1.4.3)
within the NTD was parametrised as Tetrahedron-Shaped Zinc Divalent
Cation[114]. One Na+ and two Mg2+ cations are parameterised in stand-
ard 12-6 LJ Nonbonded Model[115].
Simulation
The system building was completed with Ambertool tLEaP: Addi-
tional Na+ ions were introduced to counter the overall negative charge
of the intasome. Finally the system was placed in a cubic simulation
box filled with TIP3BOX water residues. The periodic boundary of the
system was set to minimum distance of 14 A˚ from the intasome surface
to prevent artifact interaction of the system with itself across periodic
boundary. The total simulation cell size amounted to cubic cell with
143.027 A˚ of length in each dimension.
Simulations were run using Namd[116] software with Amber[113] force-
field on Ranger and Kraken supercomputing clusters of Teragrid/XSEDE.
The simulation parameters include a cut-off radius of 12 A˚, imposed
to limit computational cost. Standard Amber scaling factor of
1
1.2
=
0.83(3) was applied to non-bonded (van der Waals) interaction between
1–4 bonded atoms. Long-range electrostatic interactions were treated
with regular cubic Particle Mesh Ewald summation with gridsize 144 A˚,
slightly larger than the periodic boundary.
All MD steps were simulated in the isothermal isobaric (NPT) en-
semble maintained at temperature 300 K using a Langevin thermostat
with damping coefficient γ=5 ps−1, and pressure 1 bar by a Berendsen
barostat with relaxation time of 0.1 ps with default water compressibil-
ity 4.57 · 10−5 bar−1. Each simulation is performed in discrete timestep
iterations of 2 fs or 2 · 10−15 s.
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4.1.2. Model validation
Short single simulations were run for the protein–DNA receptor, drug
ligand and complete system to validate the input data. Validation in-
cluded measuring root mean square deviation (RMSD) of the protein
and DNA backbone, visual inspection of the active centre with a special
focus on receptor–Mg–ligand bonds, ligand conformation and Zn-HHCC
complex to verify structure stability.
Intasome stability analysis
In the first step the stability of the complex consisting of protein,
cations and nucleic acid without the drug, was tested in short simulation.
The system’s energy was minimised in 2 000 steps of steepest descent in
the absence of constraints and annealed from 50 to 300 K. The system
was annealed again from 50 to non-physiological 550 K over 4 000 to
confirm structure stability under the chosen force field in wider range of
conditions.
Finally, the system was equilibrated for 200 ps with no constraints
applied. Snapshots of structure were collected at each 100th step of equi-
libration.
Drug model stability analysis
The newly parametrised drug model was validated through a short
simulation to verify the structural stability of parametrisation. The drug
was minimised for 5 000 steps of steepest descent in the absence of con-
straints and annealed from 50 to 300 K over 25 000 steps. The equilibra-
tion covered 100 ps in 50 000 simulation steps. Snapshots of the structure
were collected at each 500th step of equilibration.
Stability analysis of complete inhibited intasome complex
The complete complex of protein, cations, nucleic acid and RLT was
tested for stability. The system was minimised for 5 000 steps of steepest
descent in the absence of constraints and annealed from 50 to 300 K over
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25 000 steps. The equilibration covered 400 ps in 200 000 simulation steps.
Snapshots of structure were collected at each 500th step of equilibration.
Validation results
All tested systems show high stability during the annealing phase.
The maximum measured RMSD for backbone atoms of 1.66 A˚ was ob-
served at the last step of annealing at 550 K.
No unexpected behaviour was observed for either drug, intasome or
complete complex. Tetrahedral Zn-HHCC complex remains stable. The
active centre preserves its overall structure and while the drug explores
its conformation space its binding interactions with the receptor and Mg
ions are not broken. Although validity of drug parametrisation is hard to
verify within the scope of this project, the fact that all structures remain
stable despite relatively high temperature annealing is encouraging. It
was therefore decided to proceed with production simulations.
4.1.3. Simulation
Two sets of simulations were run. No constraints were applied to any
part of the simulated system in the first set of 20 replicas numbered nc10
to nc29 (hence the label nc for no constraints). In the second set of
10 replicas numbered rd30 to rd39 movement of parts of the DNA was
restricted by applying harmonic restraining potential (rd standing for
restricted DNA).
Minimisation and Annealing
Each simulation replica begins with 5 000 steps steepest descent phase
and annealing from 50 to 300 K over 25 000 steps.
Equilibration and simulations
Each replica was simulated in 10 stages of MD, for 500 000 steps
each, giving a total simulation time of 10 ns. Snapshots of system were
collected at each 5 000th step of simulation giving 1000 frames for each
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simulation. Data for 20 replicas (nc10–29) of unrestricted system were
collected in total.
Restricting DNA movement
In the 10 replicas with restrained DNA (rd30–39) constraints were
applied to a section at the far end of the DNA chain. The constraints
emulate restriction of movement when the simulated strand is only a
section of a longer chain. It also reduces the size of the phase-space for
the system to explore. The eleven base-pairs most distant from the active
centre on each of two DNA strands (22 in total) had been restricted with
harmonic constraint force constant 4.0 kcal·mol−1·A˚−1. The restricted
part of DNA in relation to the whole structure is shown in Figure 4.4.
Figure 4.4. PFV structure showing restricted part of DNA in black, in
relation to other elements — NTD (green), CCD (yellow), CTD (orange),
DNA (red), RLT (magenta), Mg (light blue), Zn (white).
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4.1.4. Binding Energy analyses
Binding free energy was calculated using the MM-PBSA method. For
each simulation replica 800 trajectory snapshots collected after completed
equilibration were used as an input data for analysis.
Energy contributions per residue were calculated using MM-GBSA.
The trajectory snapshots analysed were the same as in the previous
method.
A modification to source code of mmpbsa module of AmberTools was
required to properly handle the RLT molecule. The standard version of
the tool does not include parameters for Fluorine which had to be added
before running analyses.
4.1.5. Principal Components Analysis
The method of principal components analysis (PCA) was applied to
all nc trajectories in order to identify dominant factors of low conver-
gence. The analyses were performed in ptraj. All trajectories were first
concatenated and stripped of irrelevant or toublesome atoms. That in-
cludes solvent molecules (water and ions), tetrahedral Zinc, RLT and
N224. Removal of N224 while not necessary for this single analysis will
make it easier to compare its results with analogous analysis of N224H
later. In the end analyses trajectories included 365 out of 366 amino acid
residues, all DNA base pairs and two Mg ions.
The frames of concatenated trajectories of selected atoms were re-
aligned against averaged frame and finally reduced to the first 100 prin-
cipal components. In the first step only eigenvalues were compared to
establish an optimal number of significant PCs.
The main analysis only takes primary PCs into account to visualise
and explain the nature of movements and possibly their correlation with
calculated binding energy.
A modification of ptraj source code was required to properly handle
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the complete system. The standard version of the tool only works with
systems no larger than 3 333 atoms. The array containing atoms positions
had to be incresed from standard 10 000 and the tool had to be recompiled
before running analyses.
4.2. Results
4.2.1. Minimisation and Equilibration
The RMSD of protein Cα atoms will be used as a simplified one dimen-
sional metric of system evolution to get some insight into its behaviour,
especially the equilibration in the first phase and statistical convergence
in analysis phase.
The system relaxes quickly during the initial phase of simulation — as
seen on Figure 4.5 — and starts levelling off after around 1 ns. Therefore,
the snapshots from 200 to the end of simulation (1 000) are used as a
production phase in all subsequent analyses, giving 800 snapshots or 8 ns
worth data for each replica.
RMSD for some replicas (e.g. nc14) rises significantly higher (7–8 A˚)
than most other replicas (3–5 A˚), but closer visual analysis of trajectory
provides explanation in terms of NTD rotation. This motion appears to
have no effects on the active site. This explanation is confirmed later by
results of further analyses.
The results of simulations with restricted DNA do not differ signi-
ficantly from those of unrestricted dynamics. As seen on Figure 4.6 the
system equilibrates around the same time (2 ns) and stays within 2–5 A˚.
4.2.2. System stability per residue
The root mean square fluctuation (RMSF) per residue averaged over
whole data-sets gives us a rough idea of the relative stability of different
parts of the system.
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Figure 4.5. Evolution of RMSD for unrestricted PFV monomer complex
Cα atoms vs first frame throughout simulation time for all 20 replicas
(nc10–29). For all replicas system relaxes quickly during initial 2 ns and
fluctuates freely within reasonable range afterwards.
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Figure 4.6. Evolution of RMSD for partially restricted PFV monomer
complex Cα atoms vs first frame throughout simulation time for all 10
replicas (rd30–39). For all replicas system relaxes quickly during initial
2 ns and fluctuates freely within reasonable range afterwards.
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Figure 4.7. Comparison of all-atoms Root Mean Square Fluctuations
per residue between unrestricted (nc) and partially restricted (rd) sys-
tems. Clearly visible difference for restricted DNA (residues 375–410).
Fluctuation of protein residues within contact range of DNA is also not-
ably reduced.
The results for both data-sets (nc and rd respectively) confirms what
could be expected from the structure (Figure 4.7), exposed residues
have more freedom of movement than those hidden far from the surface.
Residues within the active centre — as well as those in close contact with
DNA — stay within 3A˚ of their original positions thanks to interactions
with the drug and DNA in addition to simple sterical obstacles from
neighbouring residues.
Exposed residues on the other hand move as far as 4A˚ and farther.
The NTD shows larger flexibility, as it is not stabilised by interactions
with any other part of the system. Similarly, more distant DNA base-pairs
fluctuate freely. The CTD, located between the domains shows interme-
diate behaviour.
RMSF for system with restricted DNA movement predictably differs
from unrestricted system significantly. Apart from the obvious difference
for restricted DNA base-pairs, and their immediate sequential neigh-
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bours, protein residues within interaction distance from (not explicitly
restricted parts of) the DNA, fluctuate about half as much as in the un-
restricted system. The compact CCD is in direct contact with the DNA
and consequently has all its residues RMSF values scaled down (residues
110–310), while the more distant NTD seems not to be affected at all,
and CTD only to a limited extent. For domains position in relation to
the active centre and restricted part of the DNA see Figure 4.4. All these
observations are consistent with what is to be expected when constraints
are applied to part of the system.
4.2.3. Binding Free Energy
The calculated binding free energies for both restrained (-21 kcal·mol−1)
and unrestrained (-25 kcal·mol−1) definitely confirm binding character of
interaction between RLT and PFV intasome. Detailed binding energy
breakdown into components for both data sets is presented in Table 4.1.
system nc rd
∆G stdev ∆G stdev
component [kcal/mol] [kcal/mol]
∆ 〈EvdW 〉 -42.79 7.08 -42.85 7.27
∆ 〈Ecoulomb〉 -49.72 20.16 -40.58 9.51
∆ 〈EMM〉 subtotal -92.51 21.70 -83.43 12.39
polar 71.99 16.39 67.01 9.22
nonpolar -5.34 0.39 -5.43 0.42
∆ 〈GPBSA〉 solvation subtotal 66.65 16.25 61.58 9.17
total -25.87 10.01 -21.85 9.44
Table 4.1. Binding free energy components comparison between un-
restricted system (nc) and system with restricted DNA movement (rd).
Detailed desctiption of components in section 2.6.
The 4 kcal·mol−1 of difference in total binding energy between both
datasets seems significant. However, the high standard deviation of the
results means they require more cautious interpretation.
More detailed analysis of gathered numerical data was performed by
calculating the distribution of energy values for all collected data-points.
As seen in Figure 4.8 both datasets distributions converge to normal
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Figure 4.8. Normalised Frequency distribution function. Relatively
good convergence to normal distribution may still be improved by ad-
ditional data. Distribution for both unrestrained (nc) and partially re-
strained (rd) systems are plotted separately, as well as distribution for
both datasets treated together (all).
distributions. The convergence is far from ideal though, especially the
peak is heavily distorted. Additional data is required for better coverage
of phase-space to improve the resolution of distribution. Most free energy
values are negative (favourable) throughout all simulation replicas with
exceptions constituting less then 0.5% of all data-points.
4.2.4. Distribution of results per replica
Finally, the average binding energy and standard deviation was cal-
culated for each simulation replica separately with results presented in
Figure 4.9.
Due to the limited amount of data, the difference between results
of completely unrestrained and partially restrained datasets are hard to
distinguish from noise. Free energy values averages for whole datasets
are dwarfed by difference between single replicas within datasets.
Nevertheless, the results confirm drug binding by PFV intasome.
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Figure 4.9. Binding Free Energy results from MM-PBSA analyses. Av-
erage binding free energy with standard deviation per replica. No signi-
ficant difference between unrestricted (nc10–29) and partially restricted
(rd30–39) datasets visible. Differences between single replicas averages
within data-set are clearly larger than between datasets averages, big
enough to explain necessity of multiple runs.
4.2.5. Per residue decomposition
The results of Binding Free Energy decomposition per residue are
plotted in Figure 4.10. All values for NTD residues are expectedly null
within error margin. Only eight protein residues, all of which are pre-
dictably located in CCD, and the three closest DNA base-pairs have
attractive contributions larger than -0.5 kcal·mol−1. Detailed numerical
results are presented in Table 4.2 for protein and Table 4.3 for non-protein
residues. Among those significant contributors are all three of D,D(35)E
motif residues and two notable residues (G187, Y212) identified for giv-
ing resistance to HIV mutants in analogous positions. All except one are
preserved between PFV and HIV-1 integrases. Positions of contributing
residues are shown in Figure 4.11. All contributing residues are located
within the active centre area, and are in direct contact with either RLT
or Mg.
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Figure 4.10. Binding free energy decomposition per residue. Negligible
contribution of NTD residues not presented. All labelled residues with
significant contribution values are in direct contact with either RLT or
Mg.
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Figure 4.11. Residues contributing to calculated binding energy, in
colours — DDE motif (green), residues with reported resistance giving
mutations G187 and Y212 (black), non-conserved Q186 (red), P214 and
Q215 (orange) in relation to other elements — CCD (yellow), DNA (red),
RLT (magenta), Mg (light blue).
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∆G [kcal/mol] protein
nc rd PFV HIV-1 note
-3.63 -3.46 D128 D64 DDE
-2.86 -3.30 D185 D116 DDE
-1.42 -0.74 Q186 N117 only non-conserved residue
-0.68 -0.83 G187 G118 MK-2048 resistant G118R [117]
-3.86 -3.51 Y212 Y143 RLT resistant Y143R[118]
-2.66 -2.72 P214 P145
-0.72 -0.65 Q215 Q146
-2.40 -2.07 E221 E152 DDE
Table 4.2. Residues with significant binding energy contribution and
their HIV-1 IN analogues.
∆G [kcal/mol]
nc rd residue
-0.82 -0.40 DG
-2.14 -2.24 DC
-2.64 -3.17 DA3
14.73 9.15 Mg
7.10 8.33 Mg
-27.36 -25.25 RLT
Table 4.3. Binding energy contributions of non-protein residues.
Residues DC and DA3 belong to CAOH-3’ dinucleotide. DG is a com-
plementary base of DC.
The only unexpected result are the highly positive (unfavourable)
values of ∆G for Mg2+ ions. It will nevertheless be ignored as the method
is known for poor handling of metal ions. Removing the Mg ions from the
simulation does not seem to be a good choice considering the role they
play in drug/DNA binding, but ignoring the values in the final result
means biased results for all other residues — all partial contributions
ought to sum to the previously calculated total binding energy. However,
the exact numerical values for other residues are not as important at this
stage as their relative contributions.
4.2.6. Principal Components Analysis
Comparison of Principal Components eigenvalues shows a clear cutoff
after third component (Figure 4.12).
Projecting original structure along eigenvectors of principal compon-
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Figure 4.12. First 20 PC Eigenvalues of movement within PFV+DNA
complex, Predominance of three primary eigenvectors clearly visible.
ents reveals that three primary components consist of NTD rotation
around three orthogonal axis. The fourth PC includes some movement
of DNA.
In conclusion, the PCA confirms the earlier results suggesting the
internal movements of the complex is dominated by a NTD and DNA
flexibility, which are rather the consequences of limiting the system to a
monomer with freely rotating NTD and DNA outer termini, which is not
a biologically meaningful result.
It is not clear whether the analysed PCs have significant effect on
active centre binding affinity to the ligand. The analysis of correlation
between the five principal components and binding energy components
does not show any obvious connection (Table 4.4).
4.2.7. Conclusions
Initial findings confirm drug binding by the PFV intasome but low
convergence means a much larger number of simulations need to be run
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Energy component PC1 PC2 PC3 PC4 PC5
∆ 〈EvdW 〉 0.07 -0.03 0.16 0.04 0.05
∆ 〈Ecoulomb〉 0.14 -0.32 0.10 -0.29 0.13
∆ 〈EMM〉 subtotal 0.15 -0.30 0.14 -0.25 0.13
polar -0.10 0.30 -0.16 0.15 -0.10
nonpolar 0.12 -0.01 0.09 -0.04 0.28
∆ 〈GPBSA〉 solvation subtotal -0.10 0.30 -0.16 0.15 -0.09
∆G total 0.16 -0.17 0.05 -0.30 0.14
Table 4.4. Correllation between principal components of nc trajectories
movements and MM-PBSA calculated binding energy in wild type in-
tasome monomer. PC4 gets the highest correlation coefficient for total
binding energy
in parallel to obtain precise results for binding energy values. DNA flex-
ibility seems to play a role in binding but this role is difficult to explain
without additional analyses. Destabilising flexibility of DNA and NTD
needs to be addressed through either restricting it by simulating sta-
bilising interactions of larger biologically relevant complex, or through
removing them from the picture completely by simulating the active
centre’s immediate neighbourhood only.
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5. Optimal system size for accurate
simulation of PFV Integrase active
centre
In chapter 4 the possibility of running binding energy calculations
of the PFV complex with RLT was established, but simulation of the
monomer produced poorly converged results. It is essential to find what
optimal subset of natural biological system could be simulated efficiently
without compromising the result accuracy beyond an acceptable level.
The DNA Integration process by definition involves at least two DNA
strands and the enzyme itself. HIV Integrase is suggested to work in a
complex of two or even four protein molecules with a number of inorganic
complements (section 3.3). Atomic simulations of such large systems are
very expensive in terms of both time and computing resources, thus it is
important to establish a minimal subsystem sufficient for useful analyses.
The series of analyses presented in this chapter were performed on
growing subsystems of the PFV Intasome dimer to establish their po-
tential in describing HIV drug binding mechanics. The purpose of the
experiment was to evaluate the ease of equilibration and the convergence
of several levels of system completeness in unbiased MD simulation. Not
only is it expected for more complete representation of a biological system
to give more accurate results, but more importantly, because of the PFV
monomer shape to observe the positive stabilising effect of complement-
ing structures between units resulting in better convergence.
The results of unconstrained wild type monomer (nc) from chapter 4
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were compared with the dimers built of DNA bound to CCD only (cd),
CCD with CTD (cc), and with the complete dimeric system (dr).
5.1. Methods
The analyses described in this chapter involve both the data obtained
in previous experiments and the results of simulations of modified sys-
tems.
Unless stated otherwise, all methods and parameters of MD simula-
tions and free energy calculations in this chapter are the same as those
of replicas with unconstrained DNA from chapter 4.
5.1.1. Input data and Simulation parameters
All simulation systems were based on a crystal structure of PFV
IN dimer[96] (PDB:3L2T). Each protein molecule is bound with DNA
double helix and a drug molecule in its active centre. Although the
complete biological system is likely tetrameric, no attempt to simulate
it was made due to prohibitive computational cost. Dimeric structure
seems to already address the most critical shortcoming of the monomer
i.e. free movement of NTD and DNA by stabilising them through the
interaction between monomeric units.
Amber standard ff03.r1 forcefield was used to parametrise the di-
mer built of two units, consisting of a protein molecule, double DNA
helix, one Na+, and two Mg2+ cations each. The Zn2+ ion chelated
by the tetrahedral HHCC motif within the NTD was parametrised as
Tetrahedron-Shaped Zinc Divalent Cation[114].
The systems building was completed with Ambertool tLEaP: Addi-
tional Na+ ions were introduced to counter the overall negative charge
of the intasome. Finally the systems were placed in simulation box filled
with TIP3BOX water residues to ensure a safe minimum distance from
the intasome surface to the periodic boundary condition. Truncated octa-
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Figure 5.1. Complete structure of PFV intasome dimer with inhibitor.
Parts marked by colours — Unit A: protein blue, DNA and Zn green;
Unit B: protein red, DNA and Zn yellow; both MG and RLT black.
hedron was chosen as the periodic unit for complete dimer system because
the system was getting too big for simulations. The truncated octahedron
shape being closer to spherical than that of a cube contains less space
filled with water, even with a larger minimum radius. Water molecules
are not interesting in the scope of this research, yet unnecessarily increase
demands on computing resources. The detailed breakdown of subsystems
used in simulations is presented in Table 5.1
All simulations were run using Namd[116] software with Amber[113]
forcefield on Ranger and Kraken supercomputing clusters of the Ter-
agrid/XSEDE and the Legion computing cluster of University College
London’s Information Services.
Unless explicitly stated otherwise each system was simulated in 11
independent replicas.
Minimisation and Annealing
Each simulation replica begins with 5 000 steps steepest descent phase
and annealing from 50 to 300 K over 25 000 steps (50 ps).
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structure subset CCD CCD+CTD PFV dimer PFV
code cd cc nc dr
sequence range 117–302 100–374 10–374 2x(10–374)
atoms (protein+DNA) 4 129 5 536 7 023 14 046
RLT 1 1 1 2
Zn2+ - - 1 2
Mg2+ 2 2 2 4
Na+ 28 20 16 32
simulation box iso 14 iso 14 iso 16 oct 16
water residues 40 802 45 343 89 925 56 136
total atoms 126 618 141 640 276 874 182 606
Table 5.1. Subsystems of wildtype PFV dimer used in simulations.
Code is used in naming datafiles, usually with replica number. Number
of Na+ ions include one ion per unit from original PDB structure with
the rest added to neutralise the overall charge. Simulation box entry
describes minimum distance (in A˚) between the intasome surface and
the wall, and box shape: cubic (iso) for most structures and truncated
octahedral (oct) for the complete dimer.
Equilibration and production simulations
Each replica was simulated in stages of MD, for 100 000 – 500 000 steps
each, giving a total simulation time 10 ns consisting of 5 000 000 timesteps
2 fs each. Snapshots of system were collected at each 5 000th step of
simulation giving 1000 frames for each simulation.
5.1.2. Binding Energy
The free energy of binding between RLT and PFV active site was
calculated with MMPBSA method using the same tools and settings
as in chapter 4. For each simulation replica 800 trajectory snapshots
collected after completed equilibration were used as an input data for
analysis. Similarly, binding energy decomposition was calculated using
the same method as in chapter 4. Because the dimer contains two active
sites, all analyses were calculated twice, once for each site, treating the
other unit together with its RLT as part of a larger receptor.
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5.1.3. Symmetry
Binding free energy was calculated for each active centre separately
for each simulation step to investigate the possible correlation between
binding sites. Pearson’s correlation coefficient between binding energy
values of two active centres was tested for null hypothesis. X = Ga and
Y = Gb were put into Equation 2.11 giving Equation 5.1:
r(Ga, Gb) =
∑
t
(
Ga(t)− G¯a
) (
Gb(t)− G¯b
)√∑
t(Ga(t)− G¯a)2
∑
t(Gb(t)− G¯b)2
(5.1)
5.2. Results
5.2.1. Equilibration
In the first step of the analysis the distribution of RMSD was com-
pared to roughly estimate the convergence of trajectories and relative
stability of all systems. While not very telling in details it may be used
as a first approximation for more advanced analyses. RMSD distributions
were calculated for positions of all Cα for protein and P for DNA, not
just active centre. While this may seem counterintuitive, the point of this
comparison is to look at the whole system. It has already been shown
in chapter 4 that large scale domain movements are disruptive for the
analysis even without having any obvious effect on the active centre.
RMSD
system mean stdev
cd 2.20 0.46
cc 2.14 0.43
nc 3.27 1.19
dr 1.64 0.22
Table 5.2. RMSD distribution for all sizes of simulation system. Sys-
tem codes are the same as in Table 5.1. The RMSD value averaged
over whole trajectory gives a simple measure of system stability. High
standard deviation for RMSD may indicate incomplete equilibration or
low convergence.
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Figure 5.2. Comparison of RMSD distribution between simulated sys-
tems in relation to respective average structures. Complete dimer (dr)
shows the highest stability and convergence of all compared systems much
better than nc described in chapter 4. The long tail in RMSD distribu-
tion for nc structure needs not necessarily indicate any effect on active
centre but calculation of binding energy with MMPBSA method for this
system does not fare well. Incomplete dimers (cc, cd) show intermediate
behaviour.
The results of comparison between systems RMS distributions are
shown in Figure 5.2 and Table 5.2.
A complete monomer structure seems to have been the worst choice
for free-energy calculations of those tested. Relatively high standard
deviation suggests incomplete equilibration or low convergence of tra-
jectories which result is similarly high deviation of binding energy values
as found in chapter 4. While intradomain structure, including the active
centre is very well preserved, the relative interdomain movements intro-
duce a lot of variation in the atoms position measured against the average
structure.
The complete dimer structure is the most stable thanks to interdo-
main stabilising interactions between two units, and its RMSD distribu-
tion shows a sharp and clear peak around 1.5A˚. It is clearly a very good
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candidate for binding energy calculation, but for a high computational
price.
Similarly, incomplete structures consisting of single CCD, as well
those of CCD+CTD equilibrate quickly to position with deviation within
slightly over 2A˚. Their structures are small and compact enough not to
show interdomain movement observed with the complete monomer.
5.2.2. System stability per residue
10 60 110 160 210 260 310 360 410
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10.00
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cc
nc
dr
Figure 5.3. Comparison of RMSF per residue between systems of dif-
ferent sizes. Fluctuations of cd and cc about the same as for nc except
for missing parts. The difference in mean deviation between complete
monomer and its subsystems are caused by high fluctuation of NTD
without much effect on the active site and CCD. Fluctuations of all
residues within a dimer (dr) significantly lower than for any other system,
clearly confirming stabilising effect of dimerisation.
Root Mean Square Fluctuation (RMSF) per residue averaged over
each dataset presented in Figure 5.3 provides more detailed understand-
ing of differences in stability for systems of different sizes. While RMSD
showed an overall measure of internal movements for the purpose of es-
timating system stability, RMSF let us compare the relative fluctuations
between analogous parts of the systems.
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RMSF values for dimer structure is lower than monomer for all residues
— not only is the system more stable as a whole but every single residue
shows less fluctuation than respective residue in the monomer. The most
striking difference is observed for the exposed parts of DNA or NTD —
the stabilising effect of interactions between domains is clearly visible.
Intermediate overall RMSD results for cc and cd systems are now
easily explained with the results of RMSF analysis. The fluctuations
of atoms within CCD and CTD are not lower for these structures than
for nc, quite the opposite in fact. For most CCD and CTD residues in
cd and cc the fluctuations are actually higher than for nc. Removal of
one or two domains from the molecule seems to weaken the rest of the
structure, even though the overall RMSD value seemed to suggest the
opposite. The lower RMSD values of truncated molecules are explained
by very high NTD fluctuation in nc which obviously does not apply for
these structures.
5.2.3. Binding Free Energy
The truncated sequences (cc and cd) simulations were judged to be
of insufficient quality for binding energy computations, given the results
of stability analysis in subsection 5.2.2. Only complete dimer (dr) seems
to bring added value to previously analysed monomer (nc). Two binding
sites were treated independently as different trajectories for the purpose
of this analysis, doubling the total number of states taken into analysis.
The results of analysis and comparison with nc and rd are presented in
Table 5.3.
The overall binding energy for a dimer is consistent with the other
systems. The binding energy is only 0.5 kcal/mol weaker than for rd.
Not all components however show the same order of consistency. Both
van der Waals and Coulomb components show stronger binding in the
dimer and the difference is negated by a roughly equal difference for the
polar solvation component. This difference is understood to be caused
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monomer (chapter 4) dimer
system nc rd dr
∆G stdev ∆G stdev ∆G stdev
component [kcal/mol] [kcal/mol] [kcal/mol]
∆ 〈EvdW 〉 -42.8 7.0 -42.8 7.3 -44.1 4.5
∆ 〈Ecoulomb〉 -49.5 20.0 -40.6 9.5 -60.4 19.8
∆ 〈EMM〉 subtotal -92.3 21.5 -83.4 12.4 -104.5 20.1
polar 71.8 16.4 67.0 9.2 88.6 17.4
nonpolar -5.3 0.4 -5.4 0.4 -5.4 0.2
solvation subtotal 66.5 16.2 61.6 9.2 83.2 17.4
total -25.9 9.9 -21.8 9.4 -21.3 8.5
Table 5.3. Binding free energy components comparison between
monomer systems (nc and rd, see Table 4.1) and the dimer (dr). The
dataset for the dimer is represented by sum of states of both units. The
absolute values of binding energy is consistent between systems within
the standard deviation margin. Stronger binding energy component is
balanced by roughly equal difference in solvation energy.
by the different complex surface area. In the dimer a large area of each
unit is in direct interaction with the second unit, thus decreasing the
area exposed to solvent. What’s important and encouraging is that the
difference does not affect the overall binding energy.
5.2.4. Distribution of results per replica
Similarly to subsection 4.2.4 the distribution of results of binding
energy per replica was calculated and presented in Figure 5.4. Overall
distribution does not diverge from the previous experiment significantly.
One notable observation is the relative independence between binding
sites within a dimer. For some replicas the difference between binding
sites is larger then overall variation between replicas. The correlation
between binding sites will be further explored in subsequent sections.
5.2.5. Binding energy decomposition
The results of binding energy decomposition per component per active
site shows an almost complete lack of contribution from the opposite
unit (Table 5.4). This strongly hints at the independence of units in
terms of the binding process. The result seems surprising given already
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Figure 5.4. Binding Free Energy results from MM-PBSA analyses. Av-
erage binding free energy with standard deviation per replica. Differences
between two binding sites for some replicas are higher then between rep-
licas suggesting relative independence between units.
∆G [kcal/mol]
subsequence A:RLT B:RLT
A:IN -20.96 0.12
A:RLT -31.16 0.01
A:DNA -9.97 -0.05
total A -27.92 0.11
B:IN 0.13 -20.13
B:RLT 0.01 -35.29
B:DNA -0.02 -10.31
total B 0.16 -28.84
Table 5.4. Binding energy decomposition per unit within a dimer. Con-
tribution of Integrase, Raltegravir and DNA of unit A and B (in rows) to
binding of Raltegravir in active site A and B (in columns) respectively.
Contribution of the opposite unit within a dimer seem to be completely
negligible.
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established importance of complete dimeric structure for the structural
stability of the complex. This finding will be validated in subsequent
section.
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Figure 5.5. Binding free energy decomposition per residue. Only CCD
residues presented. Relative contributions of labelled residues consistent
with Figure 4.10.
The comparison of per residue decomposition results between monomer
and dimer does not show any surprises. Slightly stronger apparent bind-
ing for some residues is offset by more repulsive Mg ions (Table 5.5). This
contributions of Mg ions will be ignored as in the previous chapter. Over-
all, the relative contributions of protein residues presented in Figure 5.5
for the dimer are consistent with those found in subsection 4.2.5 for a
monomer (Figure 4.10). The shortcoming of this method with regards
to metal ions is concerning, but hopefully, limiting the focus to protein
residues shall allow the identifying some effects of the mutations.
5.2.6. Symmetry
A visual analysis of trajectories show the complex breaking its sym-
metry easily. The calculated Pearson’s correlation coefficient r ' 0.09 is
marginally significant. Given almost spherical distribution (Figure 5.6)
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∆G [kcal/mol]
nc dr residue note
-3.63 -5.09 D128 DDE
-2.86 -5.06 D185 DDE
-1.42 -0.93 Q186 only non-conserved residue
-3.86 -4.12 Y212 RLT resistant Y143R[118]
-2.66 -3.07 P214
-2.40 -3.81 E221 DDE
-17.82 -20.04 IN whole peptide
14.73 28.62 Mg1
7.10 6.41 Mg2
-27.36 -33.23 RLT
-5.74 -10.14 DNA both strands
-29.01 -28.38 total
Table 5.5. Comparison of binding energy decomposition per residue
within a unit of a dimer with a monomer (Table 4.2, Table 4.3). Con-
tribution of selected residues, whole peptide (IN), Magnesium ions, Ral-
tegravir and DNA.
Figure 5.6. Binding Free Energy correlation between dimer units. With
correlation coefficient 0.09 and almost spherical distribution on the plot
the two active centres seem to be independent from each other.
92
Chapter 5. PFV IN system size
the two active centres seem to be independent from each other. This
confirms the results of the previous sections.
5.2.7. Conclusions
It has been shown that a single PFV intasome is a poor choice for
binding energy calculations with MMPBSA analysis of MD trajectories.
Dimer structure on the other hand shows much greater potential at the
expense of far higher computational cost. By using an octahedral simu-
lation box the size of the simulation system may be reduced significantly,
thus enabling running more simulation replicas and getting more data
using the same resources.
The implications of negligible correlation between active centres for
explaining enzyme function are not clear at the moment. The direct
result of this fact is however a possibility of using data for both units as
independent trajectories for the purpose of some analyses, most notably
MMPBSA.
At this stage of research the results’ actual meaning is that they will
constitute a reference for further experiments. As with most of exper-
iments and simulations involving energy measurement, obtained values
only have meaning in relation to a point of reference.
The evaluation of PFV-IN intasome dimeric structure as a viable
model for HIV IN shall be approached by introducing selective mutations
to explore the effects of differences between both homologues. If found
feasible, the evaluation of drugs vs clinically meaningful mutations[119]
will be conducted. Possible choices are Y212R — analogue of HIV-1
Y143R, for its (wildtype) binding energy contribution confirmed in sub-
section 4.2.5 — or N224H — analogue of N155H for its high measured
experimental effect of mutation on binding energy[66].
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6. Effects of HIV N155H mutant
analogue PFV N224H on measured
binding energy
The work described in the previous chapter was focused on estab-
lishing the experimental routine for simulating PFV Integrase complexes
for the purpose of explaining resistant mutations in HIV-1 Integrase,
and creating an automatic inhibitor ranking procedure. It was shown
that only a simulation of the complete dimer gives a reasonable chance
of obtaining credible results, given the overall complex structure and
consequent stability issues with incomplete structures.
The final experimental chapter of this work describes effects of point
mutation in which Asparagine in position 224 is replaced with Histidine.
The analogous mutation N155H in HIV has been reported to affect drug
binding in the study[66] of seven mutations (subsection 1.5.2). Only
two of those —the other one being F121— are residues preserved within
the lentiviral family including PFV. It is thus hoped that the molecular
dynamical causes of HIV-1 resistance will have become more easily un-
derstood through this study in accordance with the main theme of this
work.
The analyses include the data for wildtype proteins obtained in pre-
vious experiments as well as the results of new simulations involving
mutants.
Chapter 6. HIV N155H analogue PFV N224H
6.1. Methods
Unless stated otherwise all simulations and analyses methods and
parameters in this chapter are the same as in chapter 4 and chapter 5.
6.1.1. Input data and Simulation parameters
Two experiments with mutants were conducted, monomeric system
nh based on structure used in experiment nc and dimeric dh based on dr
(Table 5.1). In both cases Asn residues in position 224 in respective pdb
files were stripped of sidechains, renamed to His and had their sidechains
reconstructed with Ambertool tLEaP.
The detailed breakdown of subsystems used in simulations is presen-
ted in Table 6.1.
monomer dimer
structure subset WT N224H WT N224H
code nc nh dr dh
sequence range 10–374 10–374 2x(10–374) 2x(10–374)
atoms (protein+DNA) 7 023 7 026 14 046 14 052
RLT 1 1 2 2
Zn2+ 1 1 2 2
Mg2+ 2 2 4 4
Na+ 16 16 32 32
simulation box iso 16 iso 16 oct 16 oct 16
water residues 89 925 89 923 56 136 56 135
total atoms 276 874 276 871 182 606 182 609
Table 6.1. Subsystems of PFV N224H dimer used in simulations. Code
is used in naming datafiles, usually with replica number. Simulation box
entry describes minimum distance (in A˚) between the intasome surface
and the wall, and box shape: cubic (iso) or truncated octahedral (oct).
Number of Na+ ions include one ion per unit from original PDB structure.
Wildtype systems on which mutants were built included for comparison.
All simulations were run using Namd[116] software with Amber[113]
forcefield on Legion computing cluster.
Each system was simulated in 11 independent replicas.
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Minimisation and Annealing
Each simulation replica begins with 5 000 steps steepest descent phase
and annealing from 50 to 300 K over 25 000 steps (50 ps).
Equilibration and production simulations
Each replica was simulated in stages of MD, for 100 000–500 000 steps
each, giving a total simulation time of 10 ns consisting of 5 000 000 timesteps
2 fs each. Snapshots of the system were collected at each 5 000th step of
simulation (every 10 ps) giving 1000 frames for each simulation.
6.1.2. Binding Energy
The free energy of binding between RLT and PFV active site was
calculated with MMPBSA method using the same tools and settings as
in chapter 4 and chapter 5. For each simulation replica 800 trajectory
snapshots collected after completed equilibration were used as an input
data for analysis. Similarly, binding energy decomposition was calculated
using the same method as in chapter 4 and chapter 5. Because the dimer
contains two active sites, all analyses were calculated twice, once for each
site, treating RLT in the other unit as part of a larger receptor.
6.1.3. Symmetry
The symmetry of binding energy values between active sites was meas-
ured as Pearson’s correlation coefficient (Equation 5.1).
6.2. Results
As the simulation methods and settings were very well established at
this point no initial analyses were deemed necessary. The trajectories
were used to obtain binding energy immediately to compare susceptible
wildtype homologue values from previous chapters against these of the
molecules with RLT resistance giving mutation.
96
Chapter 6. HIV N155H analogue PFV N224H
6.2.1. Binding Free Energy
system
monomer dimer
nc nh dr dh
∆G std ∆G std ∆G std ∆G std
component [kcal/mol] [kcal/mol] [kcal/mol] [kcal/mol]
∆ 〈EvdW 〉 -42.8 7.0 -49.2 6.8 -44.1 4.5 -43.7 5.7
∆ 〈Ecoulomb〉 -49.5 20.0 -52.2 30.6 -60.4 19.8 -76.4 32.9
∆ 〈EMM〉 -92.3 21.5 -101.4 26.6 -104.5 20.1 -120.1 31.7
subtotal
polar 71.8 16.4 78.5 21.5 88.6 17.4 100.8 24.6
nonpolar -5.3 0.4 -5.6 0.2 -5.4 0.2 -5.4 0.3
solvation
66.5 16.2 72.9 21.5 83.2 17.4 95.5 24.6
subtotal
total -25.9 9.9 -28.6 9.0 -21.3 8.5 -24.7 12.7
Table 6.2. The comparison of RLT binding energy components versus
both wildtype and N224H mutant in both monomer and dimer systems.
RLT binds to N224H mutant stronger than to wildtype with goes oppos-
ite to expectation considering the reported resistance of N155H.
The results of drug binding turned out to be surprising. RLT shows
stronger affinity to both monomer and dimer mutants than to respective
wildtypes (Table 6.2). This is clearly opposite to what was expected
throughout the whole project. The free energy difference between mutant
and wildtype is around 3 kcal·mol−1 for both monomer and dimer (2.7
and 3.4 kcal·mol−1 respectively). As a consequence there is little point
in trying to explain the mutant’s resistance to RLT using these results.
6.2.2. Symmetry
The Pearson’s correlation coefficient rn224h ' −0.12 has higher abso-
lute value but opposite sign to that of the wildtype (rwt ' 0.09, subsec-
tion 5.2.6).
The visualisation of binding energy correlation in Figure 6.1 shows
broken symmetry for one unit. The overall shape is similarly symmet-
rical to wildtype with the exception of the outstanding unit B, which
skews correlation results. This finding seems to be significant because a
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Figure 6.1. Binding Free Energy correlation between for both mutant
and wild type dimer units. Clearly visible outlying single unit B of replica
dh11, otherwise the shape of main dataset is similarly symmetrical for
both systems.
large subset of results for the outstaning unit lies in the area of repulsive
interaction.
6.2.3. Distribution of results per replica
Similarly to subsection 4.2.4 the distribution of results of binding
energy per replica was calculated and presented in Figure 6.2. Nothing
of significance was observed in distribution of binding energies for nh
trajectories of the monomer, therefore given the earlier findings of its
low value the monomer was abandoned at this point.
Clearly visible is the outstanding value for unit B in replica dh11
which may signify a possible venue to follow in further research into the
binding inhibition mechanism. The binding energy values averaged over
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Figure 6.2. Binding Free Energy results from MM-PBSA analyses. Av-
erage binding free energy with standard deviation per replica. Clearly
outstanding unit dh11:B. Other binding sites, including dh11:A not vis-
ibly affected.
300 400 500 600 700 800 900 1000
-200.00
-150.00
-100.00
-50.00
.00
50.00
100.00
150.00
200.00
vdWaals
Coulomb
solvation
total
simulation frame
B
in
di
ng
 F
re
e 
E
n e
rg
y 
[k
c a
l/m
ol
]
Figure 6.3. Binding Free Energy results of MM-PBSA throughout the
simulation of unit dh11:B with breakdown into main components. Equi-
libration phase not included. Binding energy crosses into positive values
shortly after completed equilibration and stays repulsive throughout the
remainder of the simulation.
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all trajectories seem to be misleading on their own without a closer look
into details of results distribution. Closer analysis of MMPBSA results
for simulation dh11 shows positive binding energy in unit B throughout
most of its run (Figure 6.3).
The same binding energy results with and without outstanding unit
dh11:B are presented again in Table 6.3 and compared to wild type
dimer.
system dr all dh dh w/o dh11:B dh11:B
∆G std ∆G std ∆G std ∆G std
component [kcal/mol] [kcal/mol] [kcal/mol] [kcal/mol]
∆ 〈EvdW 〉 -44.1 4.5 -43.7 5.7 -44.1 5.5 -35.7 4.0
∆ 〈Ecoulomb〉 -60.4 19.8 -76.4 32.9 -78.5 31.2 -33.3 38.3
∆ 〈EMM〉 -104.5 20.1 -120.1 31.7 -122.6 29.1 -68.9 39.6
subtotal
polar 88.6 17.4 100.8 24.6 101.5 24.4 86.3 22.7
nonpolar -5.4 0.2 -5.4 0.3 -5.4 0.3 -5.0 0.2
solvation
83.2 17.4 95.5 24.6 96.1 24.5 81.3 22.6
subtotal
total -21.3 8.5 -24.7 12.7 -26.5 8.6 12.3 23.5
Table 6.3. The comparison of RLT binding energy components between
all dimer systems and outstanding dh11:B. Unfavourable binding energy
components for dh11:B in bold. Both VdW and Coulomb interaction in
dh11:B bind much weaker than in all other units, including most of dh
replicas, giving the overall repulsive effect.
While the overall binding energy for dh11:B is clearly unfavourable,
this is only the case for one unit out of two in one of eleven replicas.
The repulsive effect is not strong enough to affect the average value for
a whole ensemble of simulations. In other words it would not be visible
without detailed analysis of each unit separately. The clearly asymmet-
ric behaviour of dh11 is consistent with previously established lack of
correlation between dimer binding sites.
6.2.4. Binding energy decomposition
The results of per residue decomposition for CCD are shown in Fig-
ure 6.4 together with the difference between mutant and wildtype. The
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Figure 6.4. Binding free energy decomposition per residue. Only CCD
residues presented. The effect of mutation, calculated as a difference
between values for dh and dr is weakening of contribution of D185 even
for average of all dh replicas. More weakening effects visible for dh11:B
treated separately — D128, P214 and S217.
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∆G [kcal/mol]
dr dh ∆ dh11:B ∆ residue
-5.09 -6.04 -0.95 -3.76 1.33 D128
-5.06 -4.44 0.63 -2.76 2.30 D185
-0.93 -1.13 -0.20 -0.75 0.17 Q186
-4.12 -4.14 -0.03 -4.10 0.02 Y212
-3.07 -3.14 -0.07 -1.92 1.15 P214
-0.56 -0.42 0.14 -0.14 0.42 S217
-3.81 -4.56 -0.75 -3.71 0.10 E221
0.46 0.21 -0.25 0.15 -0.30 N224H
-1.43 -1.46 -0.02 -0.93 0.51 DG
-3.06 -3.20 -0.14 -2.03 1.03 DC
-4.03 -4.12 -0.09 -3.12 0.91 DA3
-20.04 -21.53 -1.49 -17.58 3.81 IN
28.62 32.08 3.46 22.22 -6.40 Mg1
6.41 8.36 1.95 8.75 2.35 Mg2
-33.23 -37.67 -4.44 -20.12 13.11 RLT
-10.14 -10.36 -0.23 -6.78 3.36 DNA
-28.38 -29.13 -0.75 -12.16 16.22 total
Table 6.4. Comparison of binding energy decomposition per residue
within a unit of a dimer with a monomer (Table 4.2, Table 4.3). Con-
tribution of selected residues including CAOH-3’, whole peptide (IN),
Magnesium ions, Raltegravir and DNA. The effect of mutation is weak-
ening of contribution of D185 even for dh average. More weakening effects
visible for dh11:B — CAOH-3’, D128, P214 and S217.
results reveal significant weakening difference in binding contribution for
several residues (Table 6.4). Surprisingly, N224H is not among them.
The difference between mutants His and wildtype Asn seems to be rather
strenghtening the binding. Conversely, D128 and D185 both contribute
to weakening of the binding, but more notably so do P214 and S217.
CAOH-3’ dinucleotide, together with its complementary G are also bind-
ing to mutant weaker than to wildtype. Generally, these are the results
we were hoping to obtain. With the exception of the strenghtening effect
of N224H itself, several residues within the active site show a weakening
effect that will hopefully constitute the foundation to the explanation of
viral resistance.
The results for the whole dh set however, are less clear. Some weak-
ening contributions are observed for D185 and S217, but the differences
are minute and completely overwhelmed by other residues.
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Similarly to previous experiments very high contribution of Mg ions
distorts the overall binding energy.
Spatial orientation
Residues with identified significant contribution to the difference in
overall binding energy are all located within the active site Figure 6.5.
They are not in direct contact with each other, however they all interact
with either RLT, Mg or DNA. The nature of interaction that would
result in calculated binding energies is not clear. In particular it is far
from obvious how N224H mutation affects either P214 or S217 over the
distance of ca 8A˚ (Figure 6.6).
P214 is in direct contact with RLT, which in turn interacts with
N224H through either Mg or DC of CAOH-3’. Interaction with S217
however, would have to be even more indirect, through either D185 or
E221. Both P214 and S217 are also within 6A˚ from DG complementary
to DC of CAOH-3’.
This very interesting finding was not explored further due to time
restrictions.
6.2.5. Conclusions
Given that the results for both systems are consistently opposite to
predictions we are forced to admit inadequacy of the method for the given
task. MMPBSA of PFV IN does not seem to be proper approach for
automatic drug ranking of HIV IN inhibitors. However, many questions
raised in this thesis are left unanswered, and the possibility of explaining
viral resistance through MD simulations of PFV IN remains open.
Most significantly, a single replica of N224H mutant dimer shows
repulsive interaction throughout most of its run. While the difference is
not large enough to affect the averaged result for the purpose of automatic
ranking it may yet prove to be useful in explaining the resistance of this
specific mutant.
103
Chapter 6. HIV N155H analogue PFV N224H
How can I possibly put a new idea into your heads,
if I do not first remove your delusions?
Robert A. Heinlein
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Figure 6.5. Mutant active site residues with significant in binding en-
ergy decomposition. Parts marked by colours — CCD (yellow), CTD
(orange), DNA (red), RLT (magenta), Mg (light blue). DDE residues —
D185 (red), D128 (orange), E221 (yellow). Other significant residues —
P214 (green), S217 (cyan), N224H (dark blue). For the values of binding
energy contributions see Figure 6.4 and Table 6.4.
105
Chapter 6. HIV N155H analogue PFV N224H
Figure 6.6. Mutant active site residues. Parts marked by colours —
CAOH-3’ (black), RLT (magenta), Mg (light blue). Protein residues —
D185 (red), D128 (orange), E221 (yellow), P214 (green), S217 (cyan),
N224H (dark blue). For the values of binding energy contributions see
Figure 6.4 and Table 6.4.
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